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A B S T R A C T
Background
Alcoholic hepatitis is a form of alcoholic liver disease, characterised by steatosis, necroinflammation, fibrosis, and potential complications
to the liver disease. Typically, alcoholic hepatitis presents in people between 40 and 50 years of age. Alcoholic hepatitis can be resolved
if people abstain from drinking, but the risk of death will depend on the severity of the liver damage and abstinence from alcohol.
Glucocorticosteroids are used as anti-inflammatory drugs for people with alcoholic hepatitis. Glucocorticosteroids have been studied
extensively in randomised clinical trials in order to assess their benefits and harms. However, the results have been contradictory.
Objectives
To assess the benefits and harms of glucocorticosteroids in people with alcoholic hepatitis.
Search methods
We identified trials through electronic searches in Cochrane Hepato-Biliary’s (CHB) Controlled Trials Register, CENTRAL, MED-
LINE, Embase, LILACS, and Science Citation Index Expanded. We looked for ongoing or unpublished trials in clinical trials registers
and pharmaceutical company sources. We also scanned reference lists of the studies retrieved. The last search was 20 October 2016.
Selection criteria
Randomised clinical trials assessing glucocorticosteroids versus placebo or no intervention in people with alcoholic hepatitis, irrespective
of year, language of publication, or format. We considered trials with adult participants diagnosed with alcoholic hepatitis, which could
have been established through clinical or biochemical diagnostic criteria or both. We defined alcoholic hepatitis as mild (Maddrey’s
score less than 32) and severe (Maddrey’s score 32 or more). We allowed co-interventions in the trial groups, provided they were similar.
Data collection and analysis
We followed Cochrane and CHB methodology, performing the meta-analyses using Review Manager 5 and Trial Sequential Analysis.
We presented the results of dichotomous outcomes as risk ratios (RR) and those of the continuous outcomes as mean difference (MD).
We applied both the fixed-effect model and the random-effects model meta-analyses. Whenever there were significant discrepancies
in the results, we reported the more conservative point estimate of the two. We considered a P value of 0.01 or less, two-tailed, as
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statistically significant if the required information size was reached due to our three primary outcomes (all-cause mortality, health-
related quality of life, and serious adverse events during treatment) and our post hoc decision to include analyses of mortality at more
time points. We presented heterogeneity using the I² statistic. If trialists used intention-to-treat analysis to deal with missing data, we
used these data in our primary analysis; otherwise, we used the available data. We assessed the bias risk of the trials using bias risk
domains and the quality of the evidence using GRADE.
Main results
Sixteen trials fulfilled the inclusion criteria. All trials were at high risk of bias. Fifteen trials provided data for analysis (927 participants
received glucocorticosteroids and 934 participants received placebo or no intervention). The glucocorticosteroids were administered
orally or parenterally for a median of 28 days (range 3 days to 12 weeks). The participants were between 25 and 70 years old, had
different stages of alcoholic liver disease, and 65% were men. The follow-up of trial participants, when it was reported, was up to
the moment of discharge from the hospital, until they died (a median of 63 days), or for at least a year. There was no evidence of
effect of glucocorticosteroids on all-cause mortality up to three months following randomisation neither with traditional meta-analysis
(random-effects RR 0.90, 95% CI 0.70 to 1.15; participants = 1861; trials = 15; I² = 45% (moderate heterogeneity) nor with Trial
Sequential Analysis. Meta-analysis showed no evidence of effect on health-related quality of life up to three months (MD -0.04 points;
95% CI -0.11 to 0.03; participants = 377; trial = 1; low-quality evidence), measured with the European Quality of Life - 5 Dimensions-
3 Levels (EQ- 5D-3L) scale. There was no evidence of effect on the occurrence of serious adverse events during treatment, neither
with traditional meta-analysis (random-effects RR 1.05, 95% CI 0.85 to 1.29; participants = 1861; trials = 15; I² = 36% (moderate
heterogeneity), liver-related mortality up to three months following randomisation (random-effects RR 0.89, 95% CI 0.69 to 1.14;
participants = 1861; trials = 15; I² = 46% (moderate heterogeneity), frequency of any complications up to three months following
randomisation (random-effects RR 1.04, 95% CI 0.86 to 1.27; participants = 1861; I² = 42% (moderate heterogeneity), and frequency
of non-serious adverse events up to three months’ follow-up after end of treatment (random-effects RR 1.99, 95% CI 0.72 to 5.48;
participants = 160; trials = 4; I² = 0% (no heterogeneity) nor with Trial Sequential Analysis. Nine of the trials were industry-funded.
Authors’ conclusions
We found no evidence of a difference between glucocorticosteroids and placebo or no intervention on all-cause mortality, health-related
quality of life, and serious adverse events during treatment. The risk of bias was high and the quality of evidence was very low or low.
Therefore, we are very uncertain about this effect estimate. Due to inadequate reporting, we cannot exclude increases in adverse events.
As the confidence intervals were wide, we cannot rule out significant benefits and harms of glucocorticosteroids. Therefore, we need
placebo-controlled, randomised clinical trials, designed according to the SPIRIT guidelines and reported according to the CONSORT
guidelines. Future trials ought to report depersonalised individual participant data, so that proper individual participant data meta-
analyses of the effects of glucocorticosteroids in subgroups can be conducted.
P L A I N L A N G U A G E S U M M A R Y
Glucocorticosteroids for people with alcoholic hepatitis
Review question
To assess the benefits and harms of glucocorticosteroids administered in any route, dose, and duration versus placebo or no intervention
in people with alcoholic hepatitis in terms of death, health-related quality of life, and complications.
Background
Excessive alcoholic consumption may damage the liver, causing alcoholic hepatitis. The first stage of liver damage in alcoholic hepatitis
is usually reversible if people abstain from drinking, but the risk of the disease developing further and getting more complications
increases with resumed drinking. A heavy drinker is considered a person who consumes more than 60 g to 80 g (for men) or more than
20 g (for women) alcohol per day. Only 10 to 35 people out of 100 heavy drinkers with evidence of excessive fat in the liver would
most probably develop alcoholic hepatitis. With time, alcoholic hepatitis will cause liver fibrosis (scarring of the liver) or liver cirrhosis
with complications (bleeding, infections, liver cancer, etc).
Glucocorticosteroids are considered to have anti-inflammatory effects (relieving pain, oedema, fever). They are administered to people
with alcoholic hepatitis in order to repair their liver injury. However, the benefits and harms of glucocorticosteroids are not well studied
in randomised clinical trials, and therefore, it is uncertain if they should be used in clinical practice for people with alcoholic liver
disease.
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Search date
The date of the last search was 20 October 2016.
Study characteristics
Sixteen randomised clinical trials compared glucocorticosteroids with placebo or no intervention in people with alcoholic hepatitis.
Fifteen trials provided data for analysis (927 participants received glucocorticosteroids and 934 participants received placebo or no
intervention). Glucocorticosteroids were administered orally or as an injection for a median of 28 days (range 3 days to 12 weeks). The
trial participants were between 25 and 70 years old (men: 65%) and had different stages of alcoholic liver disease. Trial participants
were followed up to the moment of discharge from the hospital, or until they died (a median of 63 days), or for at least a year. Not
all trials reported the follow-up of participants. The trials were conducted in France, India, UK, and USA. Two trials administered
pentoxifylline to both glucocorticosteroids and placebo intervention groups.
Funding
Nine of the trials were industry-funded.
Quality of evidence
The overall quality of evidence was very low, low, or moderate, and all the trials were at high risk of bias, which means that there is
possibility of drawing wrong conclusions, exaggerating benefits or underestimating harms of glucocorticosteroids because of the way
that the trials were conducted and analysed.
Key results
Glucocorticosteroids did not benefit clinical outcomes of importance to people with alcoholic liver disease, such as mortality, no matter
the cause, and health-related quality of life. In addition, glucocorticosteroids may increase the number of adverse events. We cannot
exclude benefits and harms of glucocorticosteroids but researchers need to study further their effects in high-quality, placebo-controlled,
randomised clinical trials. Such trials ought to be registered before they are launched and openly report depersonalised individual
participant data so that individual participant data meta-analysis can be conducted.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Glucocorticosteroids for people with alcoholic hepatitis
Patient or population: part icipants with alcoholic hepat it is at high risk of mortality and morbidity
Settings: hospitals and clinics
Intervention: glucocort icosteroids
Comparison: placebo or no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo or no interven-
tion
Glucocorticosteroids
All- cause mortality: 3
months following ran-
domisation
298 per 1000 278 per 1000 RR 0.90
(0.70 to 1.15)
1861
(15 RCTs)
⊕©©©1
very low
The Trial Sequent ial
Analysis-adjusted CI
was 0.36 to 2.32
Health- related quality
of life: up to 3 months
(measured with Euro-
pean Quality of Life - 5
Dimensions-3 Levels (EQ-
5D-3L) scale)
The mean value is 0.
592
The mean value is 0.
553
MD -0.04; (-0.11 to 0.
03)
377
(1 RCT)
⊕⊕©©2
low
We did not perform Trial
Sequent ial Analysis
Serious adverse events
during treatment
361 per 1000 389 per 1000 RR 1.05
(0.85 to
1.29)
1861
(15 RCTs)
⊕⊕©©3
low
The Trial Sequent ial
Analysis-adjusted CI
was 0.60 to 1.82
Liver- related mortal-
ity: up to 3 months fol-
lowing randomisation
298 per 1000 277 per 1000 RR 0.89
(0.69 to 1.14)
1861
(15 RCTs)
⊕⊕©©4
low
The Trial Sequent ial
Analysis-adjusted CI
was 0.32 to 2.45
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Any complication: up
to 3 months following
randomisation
443 per 1000 474 per 1000 RR 1.04
(0.86 to 1.27)
1861
(15 RCTs)
⊕⊕©©5
low
The Trial Sequent ial
Analysis-adjusted CI
was 0.67 to 1.63
Number of participants
with non-serious ad-
verse events: up to 3
months’ follow-up af-
ter end of treatment
51 per 1000 120 per 1000 RR 1.99
(0.72 to 5.48)
160
(4 RCTs)
⊕©©©6
very low
The Trial Sequent ial
Analysis-adjusted CI
was 0.01 to 249.60
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RCT : randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: this research provides a very good indicat ion of the likely ef fect; the likelihood that the ef fect will be substant ially dif f erent is low.
Moderate quality: this research provides a good indicat ion of the likely ef fect; the likelihood that the ef fect will be substant ially dif f erent is moderate.
Low quality: this research provides some indicat ion of the likely ef fect; however, the likelihood that it will be substant ially dif f erent is high.
Very low quality: this research does not provide a reliable indicat ion of the likely ef fect; the likelihood that the ef fect will be substant ially dif f erent is very high
1Downgraded 3 levels: 1 level due to within-study risk of bias (high overall risk of bias in all the trials); 1 level due to
inconsistency of the data (there is wide variat ion in the ef fect est imates across studies; there is lit t le overlap of conf idence
intervals associated with the ef fect est imates; presence of moderate heterogeneity: I² = 45%; heterogeneity could be
explained with select ion bias); 1 level due to imprecision of ef fect est imates (the trial sequent ial analysis showed that
addit ional evidence is needed and that we have not yet reached the required information size).
2Downgraded 2 levels: 1 level due to within-study risk of bias (high overall risk of bias in the trial); 1 level due to imprecision
of ef fect est imates.
3Downgraded 2 levels: 1 level due to within-study risk of bias (high overall risk of bias in all the trials); 1 level due to
inconsistency of the data (there is wide variat ion in the ef fect est imates across studies; there is lit t le overlap of conf idence
intervals associated with the ef fect est imates; presence of moderate heterogeneity: I² = 36%; heterogeneity could be explained
with select ion bias).
4Downgraded 2 levels: 1 level due to within-study risk of bias (high overall risk of bias in all the trials); 1 level due to
inconsistency of the data (there is wide variat ion in the ef fect est imates across studies; there is lit t le overlap of conf idence
intervals associated with the ef fect est imates; presence of moderate heterogeneity: I² = 46%; heterogeneity could be explained
with select ion bias).
5Downgraded 2 levels: 1 level due to within-study risk of bias (high overall risk of bias in all the trials); 1 level due to
inconsistency of the data (there is wide variat ion in the ef fect est imates across studies; there is lit t le overlap of conf idence
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intervals associated with the ef fect est imates; presence of moderate heterogeneity: I² = 41%; heterogeneity could be explained
with select ion bias).
6Downgraded 4 levels: 1 level due to within-study risk of bias (high overall risk of bias in all the trials); 1 level due to
inconsistency of the data (there is lit t le overlap of conf idence intervals associated with the ef fect est imates);1 level due to
imprecision of ef fect est imates (the Trial Sequent ial Analysis showed that addit ional evidence is needed and that we have
not yet reached the required information size); 1 level due to publicat ion bias (only 4 trials with a small number of part icipants
reported on non-serious adverse events).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
The term ’alcoholic hepatitis’ was used for the first time in a paper
by Beckett and colleagues in 1961 (Beckett 1961), but clinical
jaundice after excessive ethanol consumption was reported in the
literature long before that (Gerber 1973). Most probably, these
reports represented people with alcoholic hepatitis (Mendenhall
1984; Jensen 1994).
Alcoholic hepatitis is a serious formof alcoholic liver disease (injury
of the liver due to excessive alcohol consumption) (WHO 2010).
The first stage of liver damage in alcoholic hepatitis is usually re-
versible if people abstain from drinking, but the risk of progres-
sion to fibrosis and cirrhosis increases with resumed drinking (Ellis
2012). The accumulation of fat in the hepatocytes causes disrup-
tion of the mitochondrial beta-oxidation of fatty acids, accumula-
tion of lipotoxic metabolites, and release of reactive oxygen species
(Lieber 1999; Wu 1999; Petrasek 2013). Lipotoxic metabolites
and reactive oxygen species lead to cell death and liver inflamma-
tion (Wu 1999; Petrasek 2013; WHO 2013). Alcoholic hepatitis
is a histological form of alcoholic liver disease, characterised by
steatosis (the earliest stage of alcoholic liver damage) and necroin-
flammation (EASL 2012b). Alcoholic hepatitis can be resolved if
people abstain from drinking, but the risk of death will depend on
the severity of the liver damage and drinking patterns. In 20% to
40% of persistent heavy drinkers (defined as alcohol consumption
per day of more than 60 g to 80 g in men and more than 20 g in
women), alcoholic hepatitis and other complications may develop
(WHO 2013).
Severe alcoholic hepatitis may be characterised by clinically clear
signs of jaundice, coagulopathy, liver decompensation with as-
cites, portal hypertension, variceal bleeding, hepatorenal syn-
drome, hepatic encephalopathy, systemic inflammatory response
syndrome, or sepsis (Becker 1996; EASL 2012b). Typically, alco-
holic hepatitis presents in people aged between 40 and 50 years.
Among the risk factors of developing severe alcoholic hepatitis
are being female, Hispanic ethnicity, various types of alcohol,
binge drinking, poor nutrition, obesity, etc (WHO 2010). Several
composite prognostic scores exist to distinguish people with poor
prognosis from those who can become abstinent, instituting sup-
portive care, until recovery is achieved. Some of these scores, de-
signed to predict mortality, are Maddrey’s discriminant function
(Maddrey 1978), the model of end-stage liver disease (MELD)
score (Dunn 2005), the Glasgow alcoholic hepatitis score (Forrest
2005), and the age, bilirubin, international normalised ratio, cre-
atinine (ABIC) score (Dominguez 2008).
The Maddrey Discriminant Function is the most often used score
in severe alcoholic hepatitis to identify people in potential need
of glucocorticosteroids (also known as glucocorticosteroids, cor-
ticosteroids, or steroids). The one-month survival of people with
alcoholic hepatitis and with Maddrey’s score higher than 32 varied
between 50% and 65% (Carithers 1989; Phillips 2006). The Lille
Model (www.lillemodel.com) is the only validated model so far
to assess glucocorticosteroid response and is highly predictive of
death at six months (P value < 0.000001) in people with severe
alcoholic hepatitis (Louvet 2007). A LilleModel score greater than
0.45, calculated after seven days of treatment with prednisolone,
means failure to respond to treatment and predicts a six-month
mortality of about 75% (Lefkowitch 2005).
Description of the intervention
Glucocorticosteroids are used as anti-inflammatory drugs. Glu-
cocorticosteroid agents mimic the endogenous-produced gluco-
corticoid (cortisol) (Rhen 2005). Glucocorticosteroids, primarily
regulated by corticotropin, are considered to have anti-inflamma-
tory effects as well as metabolic and immunogenic effects in our
body (Rhen 2005). It is agreed that the anti-inflammatory effects
of glucocorticosteroids are mediated primarily through repression
of gene transcription (Schäcke 2002).
How the intervention might work
Glucocorticosteroids administered to people with alcoholic hep-
atitis repair the liver injury by decreasing the liver polymorphonu-
clear neutrophil (PMN) (effector cells) infiltrates and the level of
pro-inflammatory mediators such as tumour necrosis factor-alpha
(TNF-alpha), intercellular adhesion molecule 1, and interleukin
(IL)-6 and IL-8 in the liver tissue (Taïeb 2000; Spahr 2001). The
benefits of corticosteroids ensue from short-term vascular changes
(Schäcke 2002). However, adverse events have still been poorly
reported (Christensen 1995; Rambaldi 2008).
Why it is important to do this review
Over the years, a number of randomised clinical trials have stud-
ied the benefits and harms of corticosteroids for people with al-
coholic hepatitis, in order to determine the best route of admin-
istration, dose, and duration. However, results have been contra-
dictory. Some systematic reviews (Christensen 1995; Rambaldi
2008) and meta-analyses of randomised clinical trials (Reynolds
1989; Imperiale 1990; Daures 1991; Christensen 1999;Mathurin
2011) have been published. The review authors explained their
various conclusions regarding patient-orientated outcomes as be-
ing due to differences in glucocorticosteroid regimens, trial quality,
participants’ characteristics, and clinical spectrum of the disease.
Reynolds 1989 concluded that corticosteroid treatment could
help only the most severely ill people with severe alcoholic hep-
atitis characterised by high levels of serum bilirubin, prolonged
prothrombin times, and development of hepatic encephalopa-
thy. Imperiale 1990 concluded that glucocorticosteroids reduced
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short-termmortality in people with severe alcoholic hepatitis, pro-
vided that they also had hepatic encephalopathy but did not have
severe gastrointestinal bleeding. Daures 1991 concluded that fur-
ther randomised clinical trials were needed to confirm the bene-
fits and harms of glucocorticosteroids, especially in people with
severe alcoholic hepatitis. Christensen 1995, Christensen 1999,
and Rambaldi 2006 could not find sufficient proof supporting
the routine use of glucocorticosteroids in people with alcoholic
hepatitis, including those with hepatic encephalopathy. Rambaldi
2008 concluded that glucocorticosteroids did not improve overall
survival in people with alcoholic hepatitis. Based on the Trial Se-
quential Analysis of the subgroup of people with Maddrey’s score
of at least 32 or spontaneous hepatic encephalopathy, the required
information size of 2420 people for the outcome mortality was
far from reached, with only 249 participants randomised in the
six randomised trials (Rambaldi 2008). Using the Lille model,
Mathurin 2011 concluded that glucocorticosteroids significantly
improved 28-day survival in people with severe alcoholic hepatitis.
The Mathurin 2011 meta-analysis was based on individual data
from five selected randomised clinical trials and is accordingly at
risk of ’cherry picking’. This is why we decided to conduct this
Cochrane systematic review in order to assess the efficacy of glu-
cocorticosteroids in people with severe alcoholic hepatitis with or
without complications.
O B J E C T I V E S
To assess the benefits and harms of glucocorticosteroids in people
with alcoholic hepatitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised clinical trials in which glucocorticos-
teroids were assessed in people with alcoholic hepatitis, irrespec-
tive of year or language of publication or format.
We found no reports of quasi-randomised or observational studies
retrieved with our searches for randomised clinical trials, in order
to extract data on harm.
Types of participants
We included adult participants with alcoholic hepatitis, diagnosed
according to the diagnostic work-up used in the individual ran-
domised clinical trial. Alcoholic hepatitis could have been estab-
lished through clinical or biochemical diagnostic criteria or both.
We considered alcoholic hepatitis as mild if a randomised partic-
ipant had Maddrey’s score less than 32 (Maddrey’s score = 4.6 x
(prothrombin time - control time)(s) + serum bilirubin (mg per
dL)) (Maddrey 1978). Usually, people with mild alcoholic hepati-
tis do not have concomitant gastrointestinal bleeding.
We considered alcoholic hepatitis as severe at any stage of the
alcoholic liver disease with the presence of spontaneous hepatic
encephalopathy; orMaddrey’s score equal to or higher than 32.We
also examined whether there was a difference in terms of initiation
of treatmentwith glucocorticosteroids in trials using theMaddrey’s
score where severe alcoholic hepatitis was defined as equal to or
higher than 32.
Included trial participants diagnosed with severe alcoholic hep-
atitis could also manifest with hepatic encephalopathy, gastro-in-
testinal bleeding, cirrhosis (e.g. classified with Child-Pugh score -
Child-Pugh type C (Pugh 1973)), ascites, hepatorenal syndrome,
hyponatraemia, or spontaneous bacterial peritonitis.
For studies not reporting the Maddrey’s score, we used the classi-
fications for mild and severe alcoholic hepatitis as provided by the
trialists.
Types of interventions
Glucocorticosteroids administered in any route, dose, and dura-
tion versus placebo or no intervention.
We allowed co-interventions in the trial groups, provided they
were the same.
Types of outcome measures
Primary outcomes
• All-cause mortality: up to three months’ follow-up after
randomisation (the primary time point for drawing our main
conclusion); at the end of treatment (post hoc analysis); and one
year following randomisation (post hoc analysis)
• Health-related quality of life as defined by the trial authors
• Serious adverse events during treatment. We used the
International Conference on Harmonisation (ICH) Guidelines
for Good Clinical Practice’s definition of a serious adverse event
(ICH-GCP 1997), that is, any untoward medical occurrence
that results in death, is life threatening, requires hospitalisation
or prolongation of existing hospitalisation, results in persistent or
significant disability or incapacity, or is a congenital anomaly or
birth defect. We considered all other adverse events as non-
serious (see below).
Secondary outcomes
• Liver-related mortality up to three months’ follow-up after
randomisation
• Participants with any complication up to three months’
follow-up after randomisation (i.e. ascites, hepatorenal
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syndrome, spontaneous bacterial peritonitis, gastrointestinal
bleeding, hepatic encephalopathy, nonobstructive jaundice,
systemic inflammatory response syndrome, sepsis, or
hepatocellular carcinoma, or a combination of any of these)
• Participants with non-serious adverse events up to three
months’ follow-up after randomisation
Exploratory analysis
• Participants with an increase of liver enzymes as defined by
the trialists
• Participants with a decrease of prothrombin index as
defined by the trialists
• Participants with a decrease of serum albumin as defined by
the trialists
Search methods for identification of studies
Electronic searches
We searched Cochrane Hepato-Biliary’s Controlled Trials Regis-
ter (Gluud 2017; September 2016), Cochrane Central Register of
Controlled Trials (CENTRAL; 2016, Issue 8) in the Cochrane Li-
brary, MEDLINE Ovid (1946 to September 2016), Embase Ovid
(1974 to September 2016), LILACS, and Science Citation In-
dex Expanded (Web of Science; 1900 to September 2016) (Royle
2003). We applied no language or document-type restrictions.
Appendix 1 shows the search strategies with the time spans of the
searches.
Searching other resources
We searched online trials registries such as ClinicalTri-
als.gov (clinicaltrials.gov), European Medicines Agency (EMA;
www.ema.europa.eu), WHO International Clinical Trial Registry
Platform www.who.int/ictrp), the Food and Drug Administration
(FDA; www.fda.gov), and pharmaceutical company sources for
ongoing or unpublished trials (last search 20 October 2016).
Data collection and analysis
We followed the available guidelines provided in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011a),
and the Cochrane Hepato-Biliary Module (Gluud 2017).We per-
formed the analyses using ReviewManager 5 (RevMan 2014) and
Trial Sequential Analysis (Thorlund 2011; TSA 2011; Wetterslev
2017). We assessed the evidence according to Jakobsen and col-
leagues (Jakobsen 2014).
Selection of studies
We retrieved the publications that we considered as potentially
eligible for inclusion, after reading their titles and abstracts. Three
review authors (CP, DV, GC) independently reviewed the full-
text publications for eligibility. The review authors assessed each
publication to determine if trial participants and the interventions
administered met the inclusion criteria. We included abstracts if
sufficient data were provided for analysis. We resolved disagree-
ments by discussion or consulting any of the remaining review
authors for arbitration.
Data extraction and management
Three review authors (CP, DV, GC) independently completed a
data extraction form for all included trials. Authors extracted gen-
eral information on the trial, such as publication title; place and
year of publication; trial design; inclusion and exclusion criteria;
preliminary sample size calculation reached or not; number of par-
ticipants randomised in each trial and following treatment allo-
cation; diagnostic work-up; age (mean or median); sex or sex ra-
tio; race; co-infection; type, dose, and route of administration of
glucocorticosteroids and their possible link with adverse events;
concurrent medications used; length of trial; and length of follow-
up. CP, DV and GC also extracted data on malnutrition whenever
it was clearly defined by the trial authors.
The review authors resolved disagreements by discussion or asking
the advice of the review arbitrator, CG.
Assessment of risk of bias in included studies
Three review authors (CP, DV, and GC) independently assessed
the risk of bias of each included trial according to the recommen-
dations in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011b), the Cochrane Hepato-Biliary Module
(Gluud 2017), and methodological studies (Schulz 1995; Moher
1998; Kjaergard 2001; Wood 2008; Savovi 2012a; Savovi
2012b; Lundh 2017). We used the following definitions in the
assessment of risk of bias.
Allocation sequence generation
• Low risk of bias: the study performed sequence generation
using computer random number generation or a random
number table. Drawing lots, tossing a coin, shuffling cards, and
throwing dice were adequate if an independent person not
otherwise involved in the study performed them.
• Unclear risk of bias: the study authors did not specify the
method of sequence generation.
• High risk of bias: the sequence generation method was not
random. We will only include such studies for assessment of
harms.
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Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. A central and
independent randomisation unit controlled allocation. The
investigators were unaware of the allocation sequence (e.g. if the
allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes).
• Unclear risk of bias: the study authors did not describe the
method used to conceal the allocation so the intervention
allocations may have been foreseen before, or during, enrolment.
• High risk of bias: it is likely that the investigators who
assigned the participants knew the allocation sequence. We will
only include such studies for assessment of harms.
Blinding of participants and personnel
• Low risk of bias: any of the following: no blinding or
incomplete blinding, but the review authors judge that the
outcome is not likely to be influenced by lack of blinding; or
blinding of participants and key study personnel ensured, and it
is unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ‘low risk’ or ‘high risk’; or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding or
incomplete blinding, and the outcome is likely to be influenced
by lack of blinding; or blinding of key study participants and
personnel attempted, but likely that the blinding could have
been broken, and the outcome is likely to be influenced by lack
of blinding.
Blinded outcome assessment
• Low risk of bias: any of the following: no blinding of
outcome assessment, but the review authors judge that the
outcome measurement is not likely to be influenced by lack of
blinding; or blinding of outcome assessment ensured, and
unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ‘low risk’ or ‘high risk’; or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding of
outcome assessment, and the outcome measurement is likely to
be influenced by lack of blinding; or blinding of outcome
assessment, but likely that the blinding could have been broken,
and the outcome measurement is likely to be influenced by lack
of blinding.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. The study used
sufficient methods, such as multiple imputation, to handle
missing data.
• Unclear risk of bias: there was insufficient information to
assess whether missing data in combination with the method
used to handle missing data were likely to induce bias on the
results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk: the trial reported the following pre-defined
outcomes: all-cause mortality, serious adverse events, and liver-
related mortality. If the original trial protocol was available, the
outcomes should be those called for in that protocol. If the trial
protocol was obtained from a trials registry (e.g.
www.clinicaltrials.gov), the outcomes sought should have been
those enumerated in the original protocol if the trial protocol
was registered before or at the time that the trial was begun. If
the trial protocol was registered after the trial was begun, those
outcomes will not be considered to be reliable.
• Unclear risk: not all pre-defined outcomes were reported
fully, or it was unclear whether data on these outcomes were
recorded or not.
• High risk: one or more pre-defined outcomes were not
reported.
For-profit bias
• Low risk of bias: the trial appeared to be free of industry
sponsorship or other type of for-profit support that may
manipulate the trial design, conduct, or analyses of results of the
trial.
• Unclear risk of bias: the trial may or may not be free of for-
profit bias as no information on clinical trial support or
sponsorship was provided.
• High risk of bias: the trial was sponsored by industry or
received other type of for-profit support.
Other bias
• Low risk of bias: the trial appeared to be free of other
factors that could put it at risk of bias.
• Unclear risk of bias: the trial may or may not have been free
of other factors that could put it at risk of bias.
• High risk of bias: there were other factors in the trial that
could put it at risk of bias.
We judged each trial as having a low, uncertain, or high risk of
bias based on the definitions described above. We included a bias
risk assessment combining all domains and judged the trials to
be at low risk of bias if none of the trial domains was assessed as
being with high or unclear risk of bias. Moreover, we considered
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trials with one or more domains with unclear or high risk of bias
as trials at high risks of bias.
Measures of treatment effect
Dichotomous outcomes
We used risk ratio (RR) with 95% confidence interval (CI) and
Trial Sequential Analysis-adjusted CI for dichotomous outcomes.
Continuous outcomes
We used mean difference (MD) with 95%CI and Trial Sequential
Analysis-adjusted CI for health-related quality of life. We planned
to use the standardised mean difference (SMD) with 95% CI if
trials used different measures for health-related quality of life.
Unit of analysis issues
Trial participants as randomised per intervention group. In case
of multiple treatment groups, we considered only the trial group
to which glucocorticosteroids were administered versus the group
that received placebo or no intervention. If a trial consisted of
more than two groups (either parallel or factorial design), we com-
pared the participants from all the glucocorticosteroid groups ver-
sus all participants from the placebo group(s). Had we been able
to include a cross-over trial from which we could extract data for
analyses, we would have used the data from the first treatment
period of the cross-over trial.
Dealing with missing data
If dichotomous or continuous data were missing in a published
report, we, whenever possible, contacted the original investigators
to request the missing data.
If trialists used intention-to-treat analysis to deal withmissingdata,
we used these data in our primary analysis. Otherwise, we used
the data that were available to us.
Dealing with missing data using sensitivity analysis
As some trials reported only per-protocol analysis results, we in-
cluded missing data by considering participants as treatment fail-
ures or treatment successes by imputing them according to the
following two scenarios:
• extreme case analysis favouring the experimental
intervention (’best-worse’ case scenario): none of the participants
who dropped out from the experimental trial group experienced
the outcome, but all of the participants who dropped out from
the control trial group experienced the outcome; including all
randomised participants in the denominator.
• extreme case analysis favouring the control (’worst-best’
case scenario): all participants who dropped out from the
experimental trial group, but none from the control trial group
experienced the outcome; including all randomised participants
in the denominator.
For continuous outcomes, as in our case health-related quality of
life, we planned to perform a ‘best-worst’ case scenario analysis
assuming that all participants lost to follow-up in the experimental
group had an improved outcome (the group mean plus 1 standard
deviation (SD)); and all thosewithmissing outcomes in the control
group had a worsened outcome (the group mean minus 1 SD)
(Jakobsen 2014). We also planned to perform ’worst-best’ case
scenario analysis assuming that all participants lost to follow-up
in the experimental group had a worsened outcome (the group
mean minus 1 SD); and all those with missing outcomes in the
control group had an improved outcome (the group mean plus 1
SD) (Jakobsen 2014).
We performed the two sensitivity scenario analyses only for our
primary outcomes.
Assessment of heterogeneity
We addressed the presence of heterogeneity in both clinical and
statistical ways.
To assess heterogeneity between the trials, we specifically examined
the degree of heterogeneity observed in the results using the I²
statistic (Higgins 2002). As thresholds for the interpretation of
the I² statistic could be misleading, we used the following rough
guide for interpretation of heterogeneity provided in the Cochrane
Handbook for Systematic Reviews of Interventions (Deeks 2011):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity*;
• 50% to 90%: may represent substantial heterogeneity*;
• 75% to 100%: considerable heterogeneity*.
*The importance of the observed value of the I² statistic depends
on (i) the magnitude and direction of effects and (ii) the strength
of evidence for heterogeneity (e.g. P value from the Chi² test, or a
CI for I² statistic).
For the heterogeneity adjustment of the required information size
in the Trial Sequential Analysis, we used diversity (D²) because
the I² statistics used for this purpose underestimates the required
information size (Wetterslev 2009).
Depending on the number of eligible trials, we planned to add
covariates to a meta-regression model to adjust for heterogeneity.
Assessment of reporting biases
Wedrew funnel plots to assess reporting biases from the individual
trials by plotting the RR on a logarithmic scale against its standard
error (Egger 1997; Sterne 2011).
For dichotomous outcomes, we tested asymmetry using the Har-
bord test in cases where Tau² was less than 0.1 (Harbord 2006),
and we planned to use Rücker 2008 in cases where Tau² was more
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than 0.1. For continuous outcomes, we planned to use the regres-
sion asymmetry test (Egger 1997), and the adjusted rank correla-
tion (Begg 1994).
Data synthesis
Meta-analysis
We performed the meta-analyses using Review Manager 5 (
RevMan 2014) and according to the recommendations stated
in the Cochrane Handbook for Systematic Reviews of Interventions
(Deeks 2011).
We presented the results of dichotomous outcomes of individ-
ual trials as risk ratios (RR) with 95% CI and the results of the
continuous outcomes as mean difference (MD) with 95% CI
and Trial Sequential Analysis-adjusted CI. We applied both the
fixed-effect model (DeMets 1987) and the random-effects model
(DerSimonian 1986) meta-analyses. If there were statistically sig-
nificant discrepancies in the results (e.g. one giving a significant
intervention effect and the other no significant intervention ef-
fect), we reported the more conservative point estimate of the two
(Jakobsen 2014). The more conservative point estimate is the esti-
mate closest to zero effect. If the two point estimates were equal, we
used the estimate with the widest CI as our main result of the two
analyses. We considered a P value of 0.025 or less, two-tailed, as
statistically significant if the required information size was reached
due to the three primary outcomes (Jakobsen 2014). Due to us ex-
panding the number of analyses conducted, we post hoc made the
alpha level even lower. We used the eight-step procedure to assess
if the thresholds for significance were crossed (Jakobsen 2014).We
presented heterogeneity using the I2 statistic (Higgins 2002). We
presented the results of the individual trials and meta-analyses in
the form of forest plots.
Where data were only available from one trial (in our case con-
tinuous data on health-related quality of life), we used Student’s
t-test (Student 1908). We planned to use Fisher’s exact test for
dichotomous data in a single trial (Fisher 1922).
Trial Sequential Analysis
We applied Trial Sequential Analysis for both dichotomous and
continuous outcomes (Thorlund 2011; TSA 2011; Wetterslev
2017), as cumulative meta-analyses are at risk of producing ran-
dom errors due to sparse data and repetitive testing of the accumu-
lating data (Wetterslev 2008; Wetterslev 2017). To control ran-
dom errors, we calculated the diversity-adjusted required infor-
mation size (DARIS) (i.e. the number of participants needed in a
meta-analysis to detect or reject a certain intervention effect) (Brok
2008; Wetterslev 2008; Brok 2009; Thorlund 2009, Wetterslev
2009; Thorlund 2010).
In our meta-analysis, we based the DARIS for dichotomous out-
comes on the event proportion in the control group; assumption
of a plausible risk ratio reduction of 20% of the risk observed
in the included trials; a risk of type I error of 1% due to more
than three outcomes, as we decided to perform post hoc analyses
on mortality at end of treatment and at one year following ran-
domisation, a risk of type II error of 20%, and the diversity of
the included trials in the meta-analysis. For health-related quality
of life, we planned to: estimate DARIS using a minimal relevant
difference of 10% of the mean response observed in the control
group; the standard deviation; alpha of 1% (Jakobsen 2014); beta
of 20%; and the diversity as estimated from the trials in the meta-
analysis (Wetterslev 2009). However, we did not conduct Trial Se-
quential Analysis because only one trial provided data on health-
related quality of life. We also calculated and reported the Trial
Sequential Analysis-adjusted CI (Thorlund 2011).
The underlying assumptionofTrial Sequential Analysis is that test-
ing for statistical significance may be performed each time a new
trial is added to themeta-analysis. We added the trials according to
the year of publication, and, if more than one trial was published
in a year, we added trials alphabetically according to the last name
of the first author. On the basis of the DARIS, we constructed
the trial sequential monitoring boundaries for benefit, harm, and
futility (Wetterslev 2008; Thorlund 2011). These boundaries de-
termine the statistical inference one may draw regarding the cu-
mulative meta-analysis that has not reached theDARIS; if the trial
sequential monitoring boundary for benefit or harm is crossed be-
fore the DARIS is reached, firm evidence may be established and
further trials may be superfluous. However, if the boundaries are
not crossed, it is most probably necessary to continue doing trials
in order to detect or reject a certain intervention effect. However,
if the cumulative Z-curve crosses the trial sequential monitoring
boundaries for futility, no more trials may be needed.
A more detailed description of Trial Sequential Analysis can be
found at www.ctu.dk/tsa/ (Thorlund 2011).
Subgroup analysis and investigation of heterogeneity
Whenever possible, we performed the following subgroup analyses
for all-cause mortality up to three months after randomisation.
• Trials at low risk of bias compared to trials at high risk of
bias.
• Trials with people with mild alcoholic hepatitis compared
to trials with severe alcoholic hepatitis, following Maddrey’s score
lower than 32 or equal to or higher than 32 or presence of
hepatic encephalopathy; or as provided by the trialists.
• Trials with glucocorticosteroid dose equal to or less than 40
mg compared to trials with glucocorticosteroid dose more than
40 mg.
• Trials with people with severe alcoholic hepatitis without
cirrhosis compared to trials with people with severe alcoholic
hepatitis with cirrhosis. If cirrhosis is classified by Child-Pugh
score, then we may be able to perform additional subgroup
analyses in order to adjust for the clinical spectrum of the disease.
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• Trials with people with severe alcoholic hepatitis without
hepatorenal syndrome compared to trials with people with severe
alcoholic hepatitis with hepatorenal syndrome.
• Trials with people with severe alcoholic hepatitis without
ascites compared to trials with people with severe alcoholic
hepatitis with ascites.
We did not perform any additional subgroup analyses to those
planned in advance.
Sensitivity analysis
We planned to undertake additional sensitivity analyses to those
specified under Dealing with missing data should we have con-
sidered it necessary (e.g. trials published as full-paper articles, ab-
stracts, and unpublished trials).
Summary of findings’ tables
We created ’Summary of findings’ tables on all review outcomes
using GRADEpro GDT 2015. The GRADE approach appraises
the quality of a body of evidence based on the extent to which one
can be confident that an estimate of effect or association reflects the
item being assessed. The quality of a body of evidence considers
within-study risk of bias, indirectness of the evidence (population,
intervention, control, outcomes), unexplained inconsistency (het-
erogeneity) of results (including problems with subgroup analy-
ses); imprecision of results (wide CIs as evaluated with our Trial
Sequential Analyses) (Jakobsen 2014), and risk of publication bias
(Balshem 2011; Guyatt 2011a; Guyatt 2011b; Guyatt 2011c;
Guyatt 2011d; Guyatt 2011e; Guyatt 2011f; Guyatt 2011g;
Guyatt 2011h; Guyatt 2013a; Guyatt 2013b; Guyatt 2013c;
Mustafa 2013; Guyatt 2017).
We defined the levels of evidence as ’high’, ’moderate’, ’low’, or
’very low’. These grades are defined as follows:
• High quality: this research provides a very good indication
of the likely effect; the likelihood that the effect will be
substantially different is low.
• Moderate quality: this research provides a good indication
of the likely effect; the likelihood that the effect will be
substantially different is moderate.
• Low quality: this research provides some indication of the
likely effect; however, the likelihood that it will be substantially
different is high.
• Very low quality: this research does not provide a reliable
indication of the likely effect; the likelihood that the effect will
be substantially different is very high.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
We identified 932 potentially relevant records through the elec-
tronic searches (Figure 1). Of these, 37 records that referred to
16 randomised clinical trials fulfilled our inclusion criteria. We
found two trials published in abstract form (Mendenhall 1977;
Richardet 1993), and fourteen trials described in full paper ar-
ticles (Helman 1971; Porter 1971; Campra 1973; Blitzer 1977;
Maddrey 1978; Shumaker 1978; Depew 1980; Theodossi 1982;
Mendenhall 1984; Bories 1987; Carithers 1989; Ramond 1992;
De 2014; Thursz 2015). Our searches retrieved no quasi-ran-
domised trials or observational studies.We identifiedno additional
references by handsearching the reference lists of articles, retrieved
through the computerised databases.
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Figure 1. Study flow diagram
14Glucocorticosteroids for people with alcoholic hepatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
Sixteen randomised clinical trials fulfilled our review protocol in-
clusion criteria (Helman 1971; Porter 1971; Campra 1973; Blitzer
1977;Mendenhall 1977;Maddrey 1978; Shumaker 1978; Depew
1980; Theodossi 1982; Mendenhall 1984; Bories 1987; Carithers
1989; Ramond 1992; Richardet 1993; De 2014; Thursz 2015).
Two were three-armed trials (Mendenhall 1977; Mendenhall
1984), one trial was a randomised trial with a two-by-two factorial
design (Thursz 2015), one trial was a cross-over trial (Richardet
1993), and the remaining were parallel, two-group design trials.
There were 1884 participants randomised in all trials. Some par-
ticipants from Mendenhall 1977 (pilot trial or feasibility trial)
continued participation inMendenhall 1984. The trials were con-
ducted in France (n = 3), India (n = 1), UK (n = 2), and USA (n
= 10) (Characteristics of included studies). All the trials reported
the sex (65% of the participants were men) and age of the partic-
ipants (range 25 years to 70 years). Four trials excluded women
(Blitzer 1977; Mendenhall 1977; Mendenhall 1984; De 2014).
Eleven trials reported to have included trial participants at differ-
ent stages of alcoholic liver disease due to hepatitis, fibrosis, or cir-
rhosis (Helman 1971; Porter 1971; Campra 1973; Blitzer 1977;
Maddrey 1978; Depew 1980; Theodossi 1982; Mendenhall 1984
Bories 1987; Ramond 1992; Thursz 2015).Most trials established
diagnosis primarily through liver biopsy. One trial included only
participants with liver cirrhosis in addition to alcoholic hepatitis
(De 2014). The remaining trials did not provide information on
the stage of disease. All the trials included participants with recent
history of alcohol consumption, increase of serum bilirubin, liver
enzymes, prolonged prothrombin time, and participants without
previous treatment with glucocorticosteroids within the last three
months before the start of the trial. Ten trials performed liver
biopsy whenever possible (Helman 1971; Porter 1971; Campra
1973; Blitzer 1977;Maddrey 1978; Shumaker 1978;Depew1980;
Bories 1987; Ramond 1992; Thursz 2015); however, it was an
inclusion criterion in only one trial, performed at the admission
and after treatment (Helman 1971).
Ten trials reported the period of trial enrolment (range of one
year to five years, with the median of three years) (Campra 1973;
Blitzer 1977; Mendenhall 1977; Maddrey 1978; Depew 1980;
Mendenhall 1984; Bories 1987; Carithers 1989; De 2014; Thursz
2015). The earliest trial began participant recruitment in 1966
(Campra 1973), and the most recently published trial began re-
cruitment in 2011 and completed it in 2014 (Thursz 2015).
Three trials followedparticipants up to one yearMendenhall 1984,
De 2014 and Thursz 2015. The remaining trials followed their
participants to the moment of discharge from the hospital or until
death occurred, with a median duration of follow-up of 63 days
(range 28 to 120).
We could extract data for analysis from all 16 trials but one
(Richardet 1993). We contacted Richardet in 2006, but we did
not receive a reply. In the remaining 15 trials, 182 participants had
mild alcoholic hepatitis and 1679 had severe alcoholic hepatitis.
The analyses of the 15 trials accounted for 927 participants ran-
domised to glucocorticosteroids, and 934 participants randomised
to placebo or no intervention.
Experimental interventions
Glucocorticosteroids (prednisolone or 6-methylprednisolone in
equivalent dose of prednisolone) were administered orally or
parenterally at different dose regimens and different durations.
Twelve trials assessed oral glucocorticosteroids at a dose equal to
or more than 40 mg prednisolone (Helman 1971; Mendenhall
1977;Maddrey 1978; Shumaker 1978; Depew 1980;Mendenhall
1984; Bories 1987; Carithers 1989; Ramond 1992; Richardet
1993; De 2014; Thursz 2015), but three trials also allowed par-
enteral administration to participants who were not able to swal-
low (Shumaker 1978; Carithers 1989; Ramond 1992). Two trials
assessed oral glucocorticosteroids at a dose less than 40 mg pred-
nisolone (Campra 1973; Blitzer 1977), and in one trial the initial
therapy was parenteral and then it was administered orally (Porter
1971). One trial used only parenteral (intravenous) glucocorticos-
teroids (Theodossi 1982).
The median duration of glucocorticosteroid administration was
28 days with a range of three days (Theodossi 1982) to 11 weeks
(De 2014): one week (Richardet 1993), three weeks (Mendenhall
1977), four weeks (Ramond 1992; Thursz 2015), 26 days (Blitzer
1977), one month (Maddrey 1978; Mendenhall 1984; Bories
1987), five weeks (Shumaker 1978; Carithers 1989), six weeks
(Helman 1971; Campra 1973; Depew 1980), 45 days (Porter
1971). The dose of prednisolone was tapered until it was stopped
in Helman 1971; Porter 1971; Campra 1973; Blitzer 1977;
Mendenhall 1977; Shumaker 1978; Depew 1980; Mendenhall
1984; Carithers 1989; and De 2014.
Control interventions
Twelve trials used identical placebos (Helman 1971; Porter 1971;
Blitzer 1977; Mendenhall 1977; Maddrey 1978; Shumaker 1978;
Depew 1980; Mendenhall 1984; Carithers 1989; Ramond 1992;
De 2014; Thursz 2015) and four trials used no intervention (
Campra 1973; Theodossi 1982; Bories 1987; Richardet 1993).
Co-interventions
Two trials administered pentoxifylline to both glucocorticosteroids
and placebo intervention groups (De 2014; Thursz 2015). There
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seemed to be no interaction between the intervention effects of
pentoxifylline and glucocorticosteroids (De 2014; Thursz 2015).
Outcomes
The Characteristics of included studies tables detail the outcomes
reported in the individual trials. Five trials reported on outcomes
with a follow-up period up to three months after randomisation
(Helman 1971; Mendenhall 1977; Bories 1987; De 2014; Thursz
2015). Twelve trials reported on outcomes at the end of treat-
ment or at the moment of discharge from the hospital (Helman
1971; Porter 1971; Campra 1973; Blitzer 1977; Maddrey 1978;
Shumaker 1978; Depew 1980; Theodossi 1982; Bories 1987;
Carithers 1989; Ramond 1992; Richardet 1993). Three trials ex-
ceeded the 12-month follow-up period (Mendenhall 1984; De
2014; Thursz 2015).
Only one trial reported health-related quality of life, using the
European quality of life-5 dimensions (EQ-5D) score registered
to Eudra CT 2009- 013897-42 and ISRCTN 88782125 and
it was reported in all the groups at three months’ follow-up af-
ter randomisation, and at one year (Thursz 2015; see Notes in
Characteristics of included studies).
None of the trials provided usable data for meta-analyses of our
exploratory outcomes.
For further details on trial characteristics, please see Characteristics
of included studies.
Excluded studies
We excluded 26 trials from the final assessment with the reasons
for their exclusion provided in Characteristics of excluded studies.
Among the excluded trials are two trials that used a nutritional
intervention in the control group (Lesesne 1978; Cabré 2000).
Although nutritional intervention as an overall intervention does
not seem to influence mortality or serious adverse events (Feinberg
2017), including the Cabré 2000 and Lesesne 1978 trials in our
reviewwould not have affected our results noticeably because these
trials were small and had very few events.
Risk of bias in included studies
Allocation
Allocation sequence generation
Based on the information that we collected from the published
reports and information from study authors, we assessed the allo-
cation sequence generation as low risk of bias in eight trials (Porter
1971; Campra 1973; Blitzer 1977; Maddrey 1978; Carithers
1989; Ramond 1992; De 2014; Thursz 2015) and as unclear in
the remaining trials (Helman 1971; Mendenhall 1977; Shumaker
1978; Depew 1980; Theodossi 1982; Mendenhall 1984; Bories
1987; Richardet 1993).
Allocation concealment
Based on the information that we collected from the published
reports and information from study authors, we assessed the al-
location concealment as low risk of bias in ten trials (Helman
1971; Porter 1971; Campra 1973; Blitzer 1977; Shumaker 1978;
Theodossi 1982; Mendenhall 1984; Carithers 1989; Ramond
1992; Thursz 2015) and as unclear in the remaining trials
(Mendenhall 1977; Maddrey 1978; Depew 1980; Bories 1987;
Richardet 1993; De 2014).
Blinding
Three trials were at high risk of performance bias as they were
open-label trials, without blinding of participants or investigators
(Campra 1973; Bories 1987; Theodossi 1982) and placebo was
used in the Richardet 1993 trial, but there was no description of it
andwe judged the risk of bias as unclear. Twelve trialswere blinded,
using identical placebo (Helman 1971; Porter 1971; Blitzer 1977;
Mendenhall 1977;Maddrey 1978; Shumaker 1978; Depew 1980;
Mendenhall 1984b: Carithers 1989; Ramond 1992; De 2014;
Thursz 2015), and hence, at low risk of bias.
We assessed five trials at low risk of detection bias (Porter 1971;
Shumaker 1978; Carithers 1989; De 2014; Thursz 2015), and the
remaining eleven trials as unclear risk of detection bias (Helman
1971; Campra 1973; Blitzer 1977; Mendenhall 1977; Maddrey
1978; Depew 1980; Theodossi 1982; Mendenhall 1984; Bories
1987; Ramond 1992; Richardet 1993).
Incomplete outcome data
We classed four trials at high risk of attrition bias because they did
not account for participants with missing outcomes (Porter 1971;
Blitzer 1977; Theodossi 1982; Thursz 2015). Eleven trials were
assessed as having low risk of attrition bias (Helman 1971; Campra
1973;Mendenhall 1977;Maddrey 1978; Shumaker 1978; Depew
1980; Mendenhall 1984; Bories 1987; Carithers 1989; Ramond
1992; De 2014).We judged the risk of bias as unclear in Richardet
1993.
Selective reporting
All trials but Richardet 1993 reported pre-defined outcomes in our
review. We assessed the remaining 15 trials at low risk of reporting
bias.
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For-profit bias
Based on the information that we collected from the published
reports, we judged two trials to be at low risk of for-profit bias
(Porter 1971; Thursz 2015). We assessed the profit-bias as unclear
in the remaining trials (Helman 1971;Campra 1973; Blitzer 1977;
Mendenhall 1977;Maddrey 1978; Shumaker 1978; Depew 1980;
Theodossi 1982; Mendenhall 1984; Bories 1987; Carithers 1989;
Ramond 1992; Richardet 1993; De 2014).
Other potential sources of bias
We did not identify other biases for any of the included trials.
We judged all trials as high risk-of-bias trials. Figure 2 and Figure
3 show our assessment of risk of bias of the published trial reports
(Characteristics of included studies).
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias domain presented as
percentages across all included studies
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias domain for each
included study
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Effects of interventions
See: Summary of findings for the main comparison
Glucocorticosteroids for people with alcoholic hepatitis
Primary outcomes
All-cause mortality
Up to three months following randomisation
In total, 258 of 927 (27.8%) participants in the group treated with
glucocorticosteroids died versus 279 of 934 (29.9%) participants
in the control group. There was no evidence of effect of gluco-
corticosteroids on all-cause mortality (random-effects RR 0.90,
95% CI 0.70 to 1.15; participants = 1861; trials = 15; I² = 45%
(moderate heterogeneity; Analysis 1.1). We observed a similar re-
sult with the Trial Sequential Analysis showing that the cumulative
Z-curve did not cross the trial sequential monitoring boundaries
for benefit or harm, nor enter the trial sequential monitoring area
for futility in order to include an intervention effect of 20% risk
ratio reduction (RRR) (Figure 4). The Trial Sequential analysis-
adjusted CI was 0.36 to 2.32. We rated the quality of the evidence
as very low (Summary of findings for the main comparison).
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Figure 4. All-cause mortality up to three months after randomisation. Fifteen trials provided data. The
diversity-adjusted required information size (DARIS) was calculated based on all-cause mortality of 30% in the
control group; risk ratio reduction in the glucocorticosteroid group of 20%; type I error of 1%; and type II error
of 20% (80% power). Trial diversity was 62%. The required information size was 6734 participants. The
cumulative Z-curve (blue line) did not cross the trial sequential monitoring boundaries for benefit or harm
(red inward sloping lines) and did not enter the trial sequential monitoring area for futility (inner-wedge with
red outward sloping lines). The green dotted lines show the conventional boundaries of the naive alpha of 5%
equal to Z-scores of +1.96 and -1.96.
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We constructed a funnel plot for publication bias, and using the
Harbord 2006 test, we found no evidence of reporting bias (P =
0.31) (Figure 5).
Figure 5. Funnel plot of comparison 1. Glucocorticosteroids versus no intervention/placebo, outcome 1.1
all-cause mortality
’Best-worst’ case scenario analysis
The ’best-worst’ case scenario analysis on mortality up to three
months after randomisation produced two different results. While
there was no evidence of effect of glucocorticosteroids with the
random-effects model (RR 0.82, 95% CI 0.64 to 1.05; I² = 47%),
there was evidence of beneficial effect with the fixed-effect model
(RR 0.74, 95% CI 0.65 to 0.84; participants = 1861; trials = 15;
I² = 47%; Analysis 3.1). The heterogeneity in both analyses was
moderate.
’Worst-best’ case scenario analysis
The ’worst-best’ case scenario analysis on mortality up to three
months after randomisation produced two different results. While
there was no evidence of effect of glucocorticosteroids with the
random-effects model (RR 0.97, 95% CI 0.73 to 1.29; I² = 62%),
there was evidence of harmful effect with the fixed-effect model
(RR 1.21, 95% CI 1.06 to 1.37; I² = 62%); Analysis 3.2).
At the end of treatment (post hoc analysis)
21Glucocorticosteroids for people with alcoholic hepatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
The treatment lasted for a median of 28 days (range 3 days to
12 weeks). In total, 162 of 907 (17%) participants in the group
treated with glucocorticosteroids died versus 202 of 917 (22%)
participants in the control group. There was no evidence of effect
of glucocorticosteroids on all-causemortality (random-effects (RR
0.87, 95% CI 0.66 to 1.15; participants = 1824; trials = 14; I²
= 42% (moderate heterogeneity); Analysis 1.1.1). We observed a
similar result with the Trial Sequential Analysis showing that the
cumulative Z-curve did not cross the trial sequential monitoring
boundaries for benefit or harm, and did not enter the trial sequen-
tial monitoring area for futility in order to exclude an intervention
effect of 20% RRR (Figure 6). The Trial Sequential Analysis-ad-
justed CI was CI 0.29 to 2.68.We rated the quality of the evidence
as very low (Summary of findings for the main comparison).
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Figure 6. All-cause mortality at the end of treatment (median 28 days (range 3 days to 12 weeks) (post hoc
analysis). Fourteen trials provided data. The diversity-adjusted required information size (DARIS) was
calculated based on all-cause mortality of 22% in the control group; risk ratio reduction in the
glucocorticosteroid group of 20%; type I error of 1%; and type II error of 20% (80% power). Trial diversity was
59%. The required information size was 9242 participants. The cumulative Z-curve (blue line) did not cross the
trial sequential monitoring boundaries for benefit or harm (red inward sloping lines) and did not enter the trial
sequential monitoring area for futility (inner-wedge with red outward sloping lines). The green dotted lines
show the conventional boundaries of the naive alpha of 5% equal to Z-scores of +1.96 and -1.96.
We constructed a funnel plot for publication bias, and using the
Harbord 2006 test, we found no evidence of reporting bias (P =
0.84) (Figure 5).
At one year following randomisation (post hoc analysis)
Three of the included trials provided data on all-cause mortality
one year following randomisation (Mendenhall 1984; De 2014;
Thursz 2015). In total, 274 of 668 (41%) participants in the group
treated with glucocorticosteroids died versus 265 of 664 (40%)
participants in the control group. There was no evidence of effect
of glucocorticosteroids on all-cause mortality (random-effects RR
1.03, 95%CI 0.91 to 1.17; participants = 1343; trials = 3; I² = 0%
(no heterogeneity among the trials); Analysis 1.1.3). We observed
a similar result with the Trial Sequential Analysis showing that the
cumulative Z-curve entered the area of futility, which excludes an
intervention effect of 20% RRR (Figure 7). The Trial Sequential
analysis-adjusted CI was CI 0.85 to 1.25. We rated the quality
of the evidence as moderate (Summary of findings for the main
comparison).
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Figure 7. All-cause mortality up to 1 year (post hoc analysis). Three trials provided data. The diversity-
adjusted required information size (DARIS) was calculated based on mortality in the control group of 40%; risk
ratio reduction of 20% in the glucocorticosteroid group; type I error of 1%; and type II error of 20% (80%
power). Trial diversity was 0%. The required information size was 1695 participants. The cumulative Z-curve
(blue line) did not cross the trial sequential monitoring boundaries for benefit or harm (red inward sloping
lines). The cumulative Z-curve crossed the inner-wedge futility line (red outward sloping lines). The green
dotted lines show the conventional boundaries of the naive alpha of 5% equal to Z-scores of +1.96 and -1.96.
Subgroup analysis and investigation of heterogeneity: all-
cause mortality up to three months after randomisation
Trials at low risk of bias compared to trials at high risk of bias
As all the trials were at high risk of bias, we could not perform
subgroup analysis on risk of bias.
Trials with people with mild alcoholic hepatitis compared to
trials with severe alcoholic hepatitis, following Maddrey’s
score lower than or equal to or higher than 32, or presence of
hepatic encephalopathy; or as provided by the trialists
There was no significant difference (P = 0.75) between the sub-
groups (mild alcoholic hepatitis RR 1.02, 95% CI 0.58 to 1.80;
participants = 182; trials = 4; I² = 0%; Analysis 2.1.1) and severe
alcoholic hepatitis (RR 0.92, 95% CI 0.73 to 1.16; participants =
1679; trials = 14; I² = 37%; Analysis 2.1.2).
Trials with glucocorticosteroid dose equal to or less than 40
mg compared to trials with glucocorticosteroid dose more
than 40 mg
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There was no significant difference (P = 0.22) between the sub-
groups of the trials with glucocorticosteroid dose less than or equal
to 40 mg (RR 0.75, 95% CI 0.50 to 1.14; participants = 1547;
trials = 10; I² = 58%; Analysis 2.2.1) and trials with glucocorti-
costeroid dose more than 40 mg (RR 1.02, 95% CI 0.79 to 1.30;
participants = 314; trials = 5; I² = 0%; Analysis 2.2.2).
Trials with people with severe alcoholic hepatitis without
cirrhosis compared to trials with people with severe alcoholic
hepatitis with cirrhosis
There was no significant difference (P = 0.83) between the sub-
groups of the trials with severe alcoholic hepatitis without cirrho-
sis (RR 0.79, 95% CI 0.18 to 3.48; participants = 123; trials =
3; I² = 77%; Analysis 2.3.1) and trials with people with severe
alcoholic hepatitis with cirrhosis (RR 0.92, 95% CI 0.74 to 1.16;
participants = 1738; studies = 12; I2 = 35%; ; Analysis 2.3.2).
As only two trials classified cirrhosis by Child-Pugh score (Bories
1987; De 2014) and we did not know what classification system
the remaining trials had used, we could not perform a subgroup
analysis in order to adjust for the clinical spectrum of the disease.
Trials with people with severe alcoholic hepatitis without
hepatorenal syndrome compared to trials with people with
severe alcoholic hepatitis with hepatorenal syndrome
There was no significant difference (P = 0.64) between the sub-
groups of the trials with people with severe alcoholic hepatitis
without hepatorenal syndrome (RR 1.00, 95% CI 0.85 to 1.17;
participants = 1382; studies = 8; I2 = 0%; Analysis 2.4.1) com-
pared to trials with people with severe alcoholic hepatitis with
hepatorenal syndrome (RR 0.56, 95% CI 0.05 to 6.49; partici-
pants = 129; studies = 2; I2 = 88%; Analysis 2.4.2). The presence
of hepatorenal syndrome was not clearly described in five trials
(Blitzer 1977; Bories 1987; Mendenhall 1977; Mendenhall 1984;
Ramond 1992).
Trials with people with severe alcoholic hepatitis without
ascites compared to trials with people with severe alcoholic
hepatitis with ascites
As we did not have data on trials with participants not having
ascites, we could analyse only the subgroup of trials including par-
ticipants with ascites (RR 0.82, 95% CI 0.60 to 1.12; participants
= 729; trials = 13; I² = 48%) (Analysis 2.5.1). In addition, the pres-
ence of ascites was not clearly described in two trials (Mendenhall
1977; Thursz 2015).
Health-related quality of life
Up to three months
Only one trial reported on quality of life at follow-up period of up
to three months, using responses to the European Quality of Life
- 5 Dimensions-3 Levels (EQ-5D-3L) (Thursz 2015). We applied
the Student’s t-test for the glucocorticosteroids versus the placebo
group. We observed no difference between the two groups (MD
-0.04 points; 95% CI -0.11 to 0.03; Analysis 1.2). We rated the
quality of the evidence as low (Summary of findings for the main
comparison). We did not perform Trial Sequential Analysis.
Up to one year
Only one trial reported on quality of life at follow-up period of
up to one year, using responses to the European Quality of Life -
5 Dimensions-3 Levels (EQ-5D-3L) (Thursz 2015). We applied
the Student’s t-test for the glucocorticosteroids versus the placebo
group. We observed no difference between the two groups (MD
0.00 points; 95% CI -0.11 to 0.10; Analysis 1.2). We rated the
quality of the evidence as very low (Summary of findings for the
main comparison). We did not perform Trial Sequential Analysis.
Serious adverse events during treatment
Fifteen trials reported number of participants with serious adverse
events during treatment. In total, 361 of 927 (38%) participants
in the group treated with glucocorticosteroids had serious adverse
events during treatment versus 338 of 934 (36%) participants in
the control group. There was no evidence of effect of glucocorti-
costeroids on the occurrence of serious adverse events (random-
effects RR 1.05, 95% CI 0.85 to 1.29; participants = 1861; trials
= 15; I² = 36% (moderate heterogeneity); Analysis 1.3). We ob-
served a similar result with the Trial Sequential Analysis showing
that the cumulative Z-curve entered the area of futility which ex-
cludes an intervention effect of 20% RRR (Figure 8). The Trial
Sequential analysis-adjusted CI was 0.60 to 1.82. We rated the
quality of the evidence as low (Summary of findings for the main
comparison).
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Figure 8. Serious adverse events during treatment. There are 15 trials providing data. The diversity-
adjusted required information size (DARIS) was calculated based on an incidence rate of serious adverse
events in the control group of 36%; risk ratio reduction of 20% in the glucocorticosteroid group; type I error of
1%; and type II error of 20% (80% power). Trial diversity was 70%. The required information size was 6566
participants. The cumulative Z-curve (blue line) did not cross the trial sequential monitoring boundaries for
benefit or harm (red inward sloping lines), but it entered the trial sequential monitoring area for futility (inner-
wedge futility line red outward sloping lines) indicating that sufficient information was provided. The green
dotted lines show the conventional boundaries of the naive alpha of 5% equal to Z-scores of +1.96 and -1.96.
Table 1 shows the number of participants with the most often
occurring serious adverse events in 14 included trials; mortality is
not included. Table 2 presents the most often occurring serious
adverse events in Thursz 2015 because this trial did not specify the
individual number of participants with a serious adverse event.
We constructed a funnel plot for publication bias, and using the
Harbord 2006 test, we found no evidence of reporting bias (P =
0.63).
’Best-worst’ case scenario analysis
There was no evidence of effect of glucocorticosteroids on serious
adverse events during treatment, with neither of the models (ran-
dom-effects model (RR 1.00, 95% CI 0.83 to 1.21; participants =
1861; studies = 15; I2 = 28%) (not important heterogeneity) and
fixed-effect model RR 0.99, 95% CI 0.89 to 1.11; participants =
1861; I² = 28% (not important heterogeneity); Analysis 4.1).
’Worst-best’ case scenario analysis
While there was evidence of harmful effect of glucocorticosteroids
with the fixed-effect model (RR 1.18, 95% CI 1.05 to 1.31; par-
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ticipants = 1861; I² = 38%), there was no evidence of effect of glu-
cocorticosteroids with the random-effects model (RR 1.11, 95%
CI 0.91 to 1.36; I² = 38%; Analysis 4.2).
Secondary outcomes
Liver-related mortality up to three months following
randomisation
In total, 257 of 927 (27.7%) participants in the group treated with
glucocorticosteroids died versus 279 of 934 (29.9%) participants
in the control group.
There was no evidence of effect of glucocorticosteroids on liver-
related mortality (random-effects RR 0.89, 95% CI 0.69 to 1.14;
participants = 1861; trials = 15; I² = 46% (moderate heterogene-
ity); Analysis 1.4). The heterogeneity among the trials was moder-
ate. We observed a similar result with the Trial Sequential Analysis
showing that the cumulative Z-curve did not cross the trial se-
quential monitoring boundaries for benefit or harm, nor enter the
trial sequential monitoring area for futility in order to include an
intervention effect of 20% RRR (Figure 9). The Trial Sequential
analysis-adjusted CI was 0.32 to 2.45. We rated the quality of the
evidence as low (Summary of findings for the main comparison).
Figure 9. Liver-related mortality up to three months after randomisation. Fifteen trials provided data. The
diversity-adjusted required information size (DARIS) was calculated based on liver- related mortality of 30% in
the control group; risk ratio reduction in the glucocorticosteroid group of 20%; type I error of 1%; and type II
error of 20% (80% power). Trial diversity was 68%. The required information size was 8059 participants. The
cumulative Z-curve (blue line) did not cross the trial sequential monitoring boundaries for benefit or harm
(red inward sloping lines) and did not enter the trial sequential monitoring area for futility (inner-wedge with
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red outward sloping lines). The green dotted lines show the conventional boundaries of the naive alpha of 5%
equal to Z-scores of +1.96 and -1.96.
Number of participants with any complication up to three
months’ follow-up after randomisation
In total, 440 of 927 (47%) participants in the group treated with
glucocorticosteroids had one or more complications versus 414 of
934 (44%) participants in the control group. There was no evi-
dence of effect of glucocorticosteroids on frequency of any com-
plications (random-effects RR 1.04, 95% CI 0.86 to 1.27; partic-
ipants = 1861; I² = 42% (moderate heterogeneity); Analysis 1.5).
We observed a similar result with the Trial Sequential Analysis
showing that the cumulative Z-curve did not cross the trial se-
quential monitoring boundaries for benefit or harm, nor enter the
trial sequential monitoring area for futility in order to include an
intervention effect of 20% RRR (Figure 10). The Trial Sequen-
tial analysis-adjusted CI was 0.67 to 1.63. We rated the quality
of the evidence as very low, mainly due to within-study bias, in-
consistency, and imprecision (Summary of findings for the main
comparison).
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Figure 10. Any complications up to three months after randomisation. Fifteen trials provided data. The
diversity-adjusted required information size (DARIS) was calculated based on any complications of 44% in the
control group; risk ratio reduction in the glucocorticosteroid group of 20%; type I error of 1%; and type II error
of 20% (80% power). Trial diversity was 75%. The required information size was 5887 participants. The
cumulative Z-curve (blue line) did not cross the trial sequential monitoring boundaries for benefit or harm
(red inward sloping lines). The cumulative Z-curve crossed the inner-wedge futility line (red outward sloping
lines). The green dotted lines show the conventional boundaries of the naive alpha of 5% equal to Z-scores of
+1.96 and -1.96.
Number of people with non-serious adverse events up to
three months following randomisation
Only four trials reported non-serious adverse events such as
Cushingoid symptoms, vertigo, and fungal lesions. There was no
evidence of effect of glucocorticosteroids on frequency of non-
serious adverse events (random-effects RR 1.99, 95% CI 0.72 to
5.48; participants = 160; trials = 4; I² = 0% (no heterogeneity);
Analysis 1.6). We observed a similar result with the Trial Sequen-
tial Analysis showing that the cumulative Z-curve did not cross the
trial sequential monitoring boundaries for benefit or harm, nor
enter the trial sequential monitoring area for futility in order to
include an intervention effect of 50% RRR (Figure 11). The Trial
Sequential Analysis-adjusted CI was 0.01 to 249.60. We rated the
quality of the evidence as very low (Summary of findings for the
main comparison).
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Figure 11. Non-serious adverse events up to three months after randomisation. Four trials provided data.
The diversity-adjusted required information size (DARIS) was calculated based on non-serious adverse events
of 5% in the control group; risk ratio reduction in the glucocorticosteroid group of 50%; type I error of 1%; and
type II error of 20% (80% power). Trial diversity was 0%. The required information size was 2698 participants.
The cumulative Z-curve (blue line) did not cross the trial sequential monitoring boundaries for benefit or
harm (red inward sloping lines) and did not enter the trial sequential monitoring area for futility (inner-wedge
with red outward sloping lines). The green dotted lines show the conventional boundaries of the naive alpha of
5% equal to Z-scores of +1.96 and -1.96.
Exploratory outcomes at the end of treatment
No trial reported on number of participants with change of level
of liver enzymes, prothrombin index, or serum albumin at the
end of treatment. This is why we could not perform the planned
exploratory analyses. Instead, post hoc, we decided to present in
a tabular way the extracted information on level of liver enzymes
reported in the trials by Campra 1973; Maddrey 1978; Theodossi
1982; and Carithers 1989 (Appendix 2); prothrombin index or in-
ternational normalised ratio reported in the trials byCampra 1973;
Maddrey 1978; Theodossi 1982; Carithers 1989; Ramond 1992
(Appendix 3); and level of serum albumin (and bilirubin - post
hoc again) reported in the trials by Campra 1973; Maddrey 1978;
Depew1980;Theodossi 1982;Carithers 1989; andRamond 1992
( Appendix 4; Appendix 5).
’Summary of findings’ table
We have presented the key results on the outcomes mortality,
health-related quality of life, serious adverse events, liver-related
mortality, all complications, and non-serious adverse events in
30Glucocorticosteroids for people with alcoholic hepatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Summary of findings for the main comparison. We assessed the
evidence as being very low to low.
D I S C U S S I O N
Summary of main results
We included 16 randomised clinical trials comparing glucocor-
ticosteroids versus placebo or no intervention in people with al-
coholic hepatitis. Fifteen of the trials provided data for analyses.
Our traditional meta-analyses showed no beneficial or detrimental
effects of glucocorticosteroids on any of our outcomes. In general,
serious and non-serious adverse events as well as complications
were poorly reported or the information was unclear, and hence,
these analyses may be subject to outcome reporting bias (Ioannidis
2009). Trial Sequential Analyses showed similar results. Based on
methodological concerns, we classified the strength of the evidence
as very low to moderate. As the trials were at high risk of bias, it
is more likely that we are overestimating benefits and overlooking
harms.
Overall completeness and applicability of
evidence
The trial participants varied according to severity of alcoholic hep-
atitis and the trials were published between 1971 and 2014. How-
ever, only 1861 participants were included. During this time pe-
riod, glucocorticosteroid interventions varied regarding dose and
duration. The small number of trials and trial participants, except
for the Thursz 2015 trial, the poor trial design and reporting,make
the results of our review inconclusive. The high risk of bias of the
trials undermines the precision of our meta-analyses results.
We were not able to assess if ethnicity had any influence on our
results, as data were either lacking or insufficient. The same ap-
plied for the nutritional status of the participants, as only one trial
reported on it (Mendenhall 1984). Mathurin and coworkers have
proposed that people with alcoholic hepatitis with Madderey’s
score of at least 32 should likely benefit from glucocorticosteroids
(Mathurin 2011). However, we did not find a significant effect of
glucocorticosteroids in this subgroup of trial participants.
This review is applicable in people with alcoholic hepatitis at dif-
ferent stages of the disease. Our meta-analyses and Trial Sequen-
tial Analyses seem to provide no evidence of benefit of gluco-
corticosteroids on all-cause mortality at one-year follow-up after
randomisation. It is also unlikely that glucocorticosteroids may
have a beneficial effect on mortality at end of treatment and three
months following randomisation; however, due tomainly impreci-
sion (the confidence interval crossed the clinical decision threshold
between recommending and not recommending treatment and
the required number of participants is far from reached), we can-
not exclude the possibility of a short-term beneficial or harmful ef-
fect.We cannot say if glucocorticosteroids may influence infection
and gastrointestinal bleeding as we had no data for meta-analysis.
However, Thursz 2015 and colleagues’ analysis shows an increase
in the number of these complications in treated participants.
Quality of the evidence
The quality of the evidence reflects only the quality of the included
trials so we cannot be certain of our conclusions. We judged the
overall quality of evidence as very low to low for all outcomes
except for all-cause mortality at one year after randomisation, for
which the quality of the evidence was moderate. All trials were at
high risk of bias, mainly because the randomisation procedures
were insufficiently reported. In addition to downgrading the trials
for within-study risk of bias, we also downgraded the trials for
imprecision of effect estimates due to the number of participants
included in the trials (all but one of the 14 trials had fewer than 400
participants), and for inconsistency of our results (there was wide
variation in the effect estimates across the trials; there was little
overlap of confidence intervals associated with the effect estimates;
and we assessed heterogeneity of the data as moderate with I² of
36% to 46%, which could be explained with selection bias). We
also found some evidence of publication bias or small study bias.
In spite of the quality of the evidence being mostly low to very
low, we are pretty confident in our recommendations regarding
implications for practice and for research. This ensues from our
analysis results and is based on the knowledge that trials at high risk
of bias overestimate benefits and underestimate harms. Therefore,
we do not find supporting evidence for using glucocorticosteroids
in clinical practice. There is definitely a need for more transparent
reporting of individual participant data (NTAWG2015; Garattini
2016).
Potential biases in the review process
The strengths of our review are that we have conducted our re-
view following the recommendations of Cochrane Hepato-Biliary
and the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011; Gluud 2017). We included only randomised clin-
ical trials in our review. This creates a bias towards benefits as
short-term randomised trials often overlook harms. We attempted
to minimise possible selection biases by using a comprehensive
search strategy.We combined searches in electronic databases with
extensive manual searches. In addition, we also searched confer-
ence proceedings and abstract books, irrespective of language. We
think it is unlikely that we have missed any published trials, but
we cannot exclude the possibility that we havemissed unpublished
trials. In fact, visual inspection of the funnel plots suggests publi-
cation bias or small trial bias on the outcomes, mortality at end of
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treatment and following threemonths after randomisation (Figure
5). We wrote to pharmaceutical companies as well as to regulatory
authorities. We made extensive attempts to avoid risk of system
and random errors. We assessed the evidence with GRADE ap-
proach.
Limitations of our review were the small number of trials and the
small total number of participants. Having in mind that hepatitis
C viral disease was discovered as late as 1989, we might have run
the risk that the included trials initiated before 1989 did not in-
clude participants with only alcoholic hepatitis (Houghton 2009).
Furthermore, our results are hampered by the quality of the in-
cluded trials as well as imprecision and severe inconsistency. Even
though all trials provided data on mortality, data on other serious
adverse events and complications were rarely reported, which calls
into question the reliability of the two latter analyses. Moreover,
by including primarily randomised clinical trials we have focused
on potential beneficial effects and overlooked the many known
harms connected with the administration of glucocorticosteroids.
Again, these flaws in our review make us suspect that benefits are
overestimated and harms are underestimated.
When conducting our Trial Sequential Analyses, we used plausible
parameters to calculate our required information sizes. However,
we only used 80% power (beta = 20%). Had we used 90% power
(beta = 10%) or less, which is relevant in meta-analyses where
one does not want to discharge a potentially relevant intervention,
then we would have obtained larger required information sizes
and wider Trial Sequential Analyses-adjusted Confidence Intervals
(Garattini 2016; Castellini 2017). Accordingly, the imprecision
may be worse than signalled by our analyses.
Agreements and disagreements with other
studies or reviews
The meta-analysis by Christensen 1995 and colleagues found no
effect of glucocorticosteroids versus placebo on mortality. This
review included data from 13 trials with 659 participants ran-
domised. Rambaldi 2008 and colleagues updated the meta-anal-
ysis by Christensen 1995, adding two more trials with 62 partic-
ipants randomised. Hence, Rambaldi 2008 and colleagues con-
cluded that depending on the estimation of the information size,
their review lacked another 1000 to 2000 participants randomised
to glucocorticosteroids versus placebo in order to be able to either
demonstrate or reject a clinically relevant 20% mortality reduc-
tion.
We found two new trials for inclusion in our review (De 2014;
Thursz 2015). However, we excluded two of the trials from the
Rambaldi and colleagues review (Rambaldi 2008) as they assessed
glucocorticosteroids versus nutrition (Lesesne 1978; Cabré 2000).
In addition, two trial reports turned out to be the same trial (
Shumaker 1978; Galambos 1984), and thus, we counted them as
one trial.
Our systematic review of pair-wise comparison randomised clini-
cal trials is in agreement with the recent meta-analysis by Buzzetti
2017. In this network meta-analysis, the authors found no signif-
icant effects of glucocorticosteroids on mortality at maximal fol-
low-up and up to 90 days of follow-up.
Due to the inclusion of the two new trials, our review now in-
cludes 1861 participants. The Thursz 2015 trial included 1103
participants and found “a reduction in the 28-day mortality in
the prednisolone-treated group on logistic regression model anal-
ysis, but there was not clear evidence of benefit, sustained beyond
this point”. Mathurin 2011 performed “analysis of individual data
from five randomised clinical trials which showed that corticos-
teroids significantly improved 28-day survival in patients with se-
vere alcoholic hepatitis”. In our present aggregate meta-analysis,
we cannot see an effect of glucocorticosteroids onmortality at ’end
of treatment’, which is quite close to 28 days.
Modern clinical guidelines recommend prescribing glucocorti-
costeroids: “Patients with severe disease (Maddrey’s Discriminant
Function (MDF) score of > 32, with or without hepatic en-
cephalopathy) and lacking contraindications to steroid use should
be considered for a four-week course of prednisolone (40 mg/day
for 28 days, typically followed by discontinuation or a 2-week
taper) (Class I, level A)” (AASLD 2010); and “First-line therapy
in patients with severe alcoholic hepatitis includes corticosteroids
or, in case of ongoing sepsis, pentoxifylline (Recommendation
B1) (see original publication for Figure 2)” (EASL 2012). In our
present aggregate meta-analysis, we cannot find a beneficial effect
of glucocorticosteroids in people with severe alcoholic hepatitis.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found no evidence of a difference between glucocorticosteroids
and placebo or no intervention on all-cause mortality, health-re-
lated quality of life, and serious adverse events during treatment.
The risk of bias was high and the quality of evidence was very low
or low. Therefore, we are very uncertain about this effect estimate.
Due to inadequate reporting, we cannot exclude increases in ad-
verse events. As the confidence intervals were wide, we cannot rule
out significant benefits and harms of glucocorticosteroids.
Implications for research
As there could be some people with alcoholic hepatitis who could
benefit from glucocorticosteroids, it could be of use for researchers
to study further the effects of glucocorticosteroids in randomised
clinical trials on short-term all-cause mortality. Additional evi-
dence evaluating the effect on health-related quality of life may
also be needed. Future trials ought to be designed according to
the SPIRIT guidelines (http://www.spirit-statement.org/) and re-
ported according to the CONSORT guidelines (www.consort-
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statement.org). Future trials ought to report individual participant
data, so that proper individual participant data meta-analyses of
the effects of glucocorticosteroids in subgroups can be conducted
(NTAWG 2015; Garattini 2016).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Blitzer 1977
Methods A prospective, double-blind randomised trial
Country: USA, 1971-1973
Analyses were not performed according to the intention-to-treat principle
Sample size calculation was not reported
Participants Demographic characteristics
Age (mean): prednisolone/placebo group 47.2/48.4
Sex: male (all participants)
“There were no significant differences between them with respect to mean age, sex,
race, duration of hospitalization prior to entry into the study, frequency of histologically
proved cirrhosis, or to the histologic severity of the alcoholic hepatitis.”
Inclusion criteria and degree of severity
“.. patients with alcoholic hepatitis whomet the following criteria after at least five days in
the hospital were included in the study: (1) recent history of heavy alcohol consumption
(more than one pint of whiskey per day or its alcoholic equivalent);
(2) hepatomegaly based on physical examination (palpable more than 5 cm below the
costal margin) and/or liver scan;
(3) total serum bilirubin greater than 5 mg/100 mL; and
(4) at least two of the following abnormalities:
(a) serum glutamic oxaloacetic transaminase (SGOT) greater than 100 Reitman-Frankel
units per ml,
(b) serum albumin concentration less than 3g/100 mL, or
(c) prothrombin time more than 2 s greater than control value
Liver biopsies were performed whenever possible, but were not required for admission
to the study.”
“14 biopsies proved alcoholic hepatitis.”
“Neither positive PPD skin tests nor active tuberculosis excluded patients from random-
ization. None of the former were encountered, and one of the latter continued to receive
INH and PAS throughout the study. If serious life-threatening infection was present,
patients’ entry into the protocol was postponed until it was eradicated. Patients with
either a history of peptic ulcer, active peptic ulcer disease, or gastrointestinal bleeding
were included.”
The study authors did not clearly describe the degree of severity of alcoholic hepatitis;
however, the participants probably had moderate to severe alcoholic hepatitis, since they
presented patients with alcoholic hepatitis who met the described criteria
Exclusion criteria
“...who had been treated with adrenocorticosteroid in the six months prior to admission
or who showed evidence of psychotic behavior precluding their cooperation during the
investigation were excluded”
Randomisation procedure
“...Patients were assigned by random, sealed-envelope technique to receive either placebo
or steroid”
Number of participants randomised
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Blitzer 1977 (Continued)
n = 33
Prednisolone group: n = 17
Placebo group: n = 16
Interventions Experimental group: oral prednisolone
Dose: “10 mg q.i.d [four times a day], for 14 days, 5 mg qid [four times a day] for 4
days, 2.5 mg qid [four times a day] for 4 days, and 2.5 nag bid [four times a day] for 4
days”
Control group: placebo tablets
Dose: the same dosage schedule as the prednisolone group
Additional interventions to the trial groups: “Patients were encouraged to eat the
standard hospital 2600-calorie diet and were offered supplements when caloric intake
seemed inadequate. Low-protein, low-sodium, and other special diets were employed as
the clinical situation dictated.”
Duration of treatment: 26 days
Follow-up after randomisation: 9 weeks
Outcomes The trial outcomes were:
• Mortality
• Liver biochemistry
• Liver histology
• Adverse events
Notes Letter sent to authors in March 2000. No answer received. No further attempts were
made as the trial was conducted between 1971-1973
One participant received placebo treatment during the trial. At the end of the therapy,
due to lack of improvement, the ward physician requested the code be broken. The
participant received a 7-day course of prednisolone. He died 17 days later; his death was
included in the mortality data of the placebo group on an intention-to-treat basis
On the 26th day treatment period, three participants in the placebo group and one in the
glucocorticosteroid group received the alternative medication on a double-blind basis
“Both prednisolone and placebo tablets were kindly supplied by the Upjohn Co., Kala-
mazoo, Michigan.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were assigned by random, sealed-
envelope technique to receive either
placebo or steroid”
Allocation concealment (selection bias) Low risk “Patients were assigned by random, sealed-
envelope technique to receive either
placebo or steroid”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Only the pharmacist was aware of the type
of therapywhich any individual patientwas
receiving.”
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Blitzer 1977 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information was provided
Incomplete outcome data (attrition bias)
All outcomes
High risk “5 participants, who had each received less
than 5 days of therapy, were subsequently
excluded from analysis. Of these, three had
left the hospital against medical advice or
withdrew from the study, and in two par-
ticipants experimental therapy had been
stopped following gastrointestinal haemor-
rhage.One bled after 4 days of therapy from
a gastric varix and the other from an un-
known site after three days of treatment.
On breaking the code at the end of the in-
vestigation, it was learned that all five par-
ticipants had been in the steroid group..
..Furthemore, the addition of two deaths
among the five excluded participants ......”
3/17 people in the prednisolone group and
0/16 people in the placebo group dropped
out (9%)
Selective reporting (reporting bias) Low risk All-cause mortality, serious adverse events,
and liver-related mortality were reported
For-profit bias Unclear risk Prednisolone and placebo tablets were sup-
plied by the Upjohn Co., Kalamazoo,
Michigan
Other bias Low risk None suspected
Bories 1987
Methods Randomised controlled trial
Country: France, 1979-1982
Analyses were performed according to intention-to-treat method
Sample size calculation was not reported.
Participants Demographic characteristics
Age: prednisolone group: average 41 years old (26 to 68); control group: average 49 years
old (30 to 70)
Sex: 16 men and 8 women in the treatment group, and 11 men and 10 women in the
control group
Inclusion criteria and degree of severity
Not stated clearly, but the average level of bilirubin was ≥ 147 + 30.78 mmol/L
Alcohol consumption: 155 g + 46 g per day in men; 140 g + 32 g per day in women
Exclusion criteria
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Bories 1987 (Continued)
48 patients were excluded due to infections (45 patients), diabetes (2 patients), and
tuberculosis (1 patient)
Randomisation procedure
Random number table
Number of participants randomised
n = 45
Prednisolone group: n = 24
Control group: n = 21
Interventions Experimental group: oral prednisolone
Dose: 40 mg/d
Control group: no intervention
Additional interventions to the trial groups: 1500 calories and 50 g of protein/d. En-
cephalopathy was treated with lactulose and neomycin. In case of infection, participants
were treated with antibiotics
Duration of treatment: 1 month
Duration of follow-up: 3 months after randomisation
Outcomes The trial outcomes were:
• Mortality
• Liver histology
• Adverse events
Notes Letter sent to authors in March 2000. No answer received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “By random number table”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) Low risk All-cause mortality, serious adverse events,
and liver-related mortality were reported
For-profit bias Unclear risk Not reported
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Bories 1987 (Continued)
Other bias Low risk None suspected
Campra 1973
Methods A prospective randomised control trial
Country: USA, 1971
Analyses were not performed according to intention-to-treat method
Sample size calculation was not reported
Participants Demographic characteristics
Age: (mean + SD): prednisolone/control group 43.1 + 11.1/42.7 + 8.1
Sex: male (%): prednisolone/control group: 8% (40)/9% (35)
Inclusion criteria and degree of severity
“.....a clinical diagnosis of severe acute alcoholic liver disease, absence of contraindication
to corticosteroids therapy, absence of a prior history of liver disease.”
Liver biopsy was not required for admission in the trial since some participants had
prothrombin time < 50% of normal value
No clear definition of severity criteria used
Exclusion criteria
Participants with other known illness or illnesses
Randomisation procedure
“...by using previously prepared sealed envelopes, patients were randomly allocated to
one of the two treatment groups”
Number of participants randomised
“50 patients entered the trial, but 5 were subsequently withdrawn when additional data
favoured another diagnosis. In one case (group 2), jaundice proved to be caused by
hepatitis B....the patient died .....2 of these patients were in group 2, one patient in
group 1; all survived. The fifth patient was removed from the trial when peptic ulcer was
diagnosed after 15 days of prednisolone therapy”
Prednisolone group:
n = 22 (20)
Control group:
n = 28 (25)
Analyses of 45 participants: 20 prednisolone + 25 control
Interventions Experimental group: oral prednisone
Dose: 0.5 mg/kg body weight daily, during 3 weeks; and then 0.25 mg/kg body weight,
daily, for additional 3 weeks
Control group: no intervention
Additional interventions to the trial groups: vitamin supplements, folic acids; “high
calorie, high protein diet was given if tolerated .......In patients with encephalopathy,
protein intake was reduced to 20 or 40 g..... and neomycin 500 x 4 times daily was given.
...In case of bleeding , vomiting and extreme anorexia, 5% or 10% solutions of dextrose
in water was administered.”
Duration of treatment: 6 weeks
Duration of follow-up: “hospital stay after randomisation ranged between 42 and 92
days, with a mean of 47 days, for group 1; and between 43 and 95 days, with a mean of
48 days, for group 2.”
45Glucocorticosteroids for people with alcoholic hepatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Campra 1973 (Continued)
Outcomes The trial outcomes were:
• Mortality
• Liver biochemistry
• Liver histology
• Adverse events
Notes Letter sent to authors in March 2000. AG Redeker answered in January 2001 (see the
risk of bias table)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...using previously prepared sealed en-
velopes, patients were randomly allocated
to one of the two treatment groups”
Allocation concealment (selection bias) Low risk Information obtained through personal
communication with the authors in 2001
reads: “they were never in the possession of
the investigators, but were kept by the de-
partment secretary who opened them upon
request”
However, the publication reads: “using pre-
viously prepared sealed envelopes, patients
were randomly allocated to one of the two
treatment groups”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “the trial was not double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “.. all statistical analyses and interpretation
were done under supervision of Dr. John
Weiner of the Department of Biostatics,
University of Southern California School
of Medicine”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “50 patients entered the trial, but five were
subsequently withdrawn when additional
data favoured another diagnosis. In one
case (group2), jaundice proved to be caused
by hepatitis B...the patient died .....2 of
these patients were in group 2, one patient
in group 1; all survived. The fifth patient
was removed from the trial when peptic ul-
cer was diagnosed after 15 days of pred-
nisolone therapy”
46Glucocorticosteroids for people with alcoholic hepatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Campra 1973 (Continued)
0/22 prednisolone group/control group 0/
28
Selective reporting (reporting bias) Low risk All-cause mortality, serious adverse events,
and liver-related mortality were reported
For-profit bias Unclear risk Not reported
Other bias Low risk Not suspected
Carithers 1989
Methods A randomised, multi central, double-blind, placebo-controlled, clinical trial
Country: USA, 1979-1984
Analyses were performed according to intention-to-treat method
Sample size calculation was reported
It was ”.. calculated that 62 patients should be entered to have a 95% chance of detecting
a difference in survival between the two groups“
Participants Demographic characteristics
Age (mean) + SD: 43.1 + 2.0 in the treatment group; 44.4 + 1.7 in the placebo group
Sex: (male (%)): 20 (57)/21 (68)
Inclusion criteria and degree of severity
”... a history of long-standing alcoholism and clinical features of alcoholic hepatitis were
evaluated by one of the principal investigators within 3 days of admission. All patients
admitted to the study had either clinical evidence of spontaneous hepatic encephalopa-
thy or a discriminant function value greater than 32 or both. Hepatic encephalopathy
was assessed using standard clinical criteria. Spontaneous hepatic encephalopathy was
considered to be present when correctable causes of encephalopathy had been excluded.
“
”Each patient had to have a negative hepatitis B surface antigen within the first 3 days
of hospitalisation and also have no history of previous viral hepatitis.“
Exclusion criteria
”Patients with gastrointestinal haemorrhage requiring transfusions, diabetes requiring
insulin administration, active infection requiring treatment, clinical and laboratory evi-
dence of acute pancreatitis, history of recent head trauma, known prior heroin addiction,
or preexisting chronic renal disease with a serum creatinine level greater than 175 mmol/
L were excluded“
Randomisation procedure
”.. Random sequences for drug or placebo were submitted to the Upjohn Company
(Kalamazoo, Michigan), which provided methylprednisolone (Medrol) in 4-mg tablets
and identical placebo tablets as well as intravenous preparations of methylprednisolone
sodium succinate (SoluMedrol) and placebo. A random code was prepared for each of
the four participating institutions such that within each group of 10 patients, 5 would
receive methylprednisolone and 5 placebo. The random code sequence was kept by an
independent source.“
Number of participants randomised
n = 67 (”...67 patients ranging in age from 25 to 66 years were entered into the study
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Carithers 1989 (Continued)
over 4 years“)
Prednisolone group
n = 36 (2 refused, 1 was excluded from analysis)
Control group
n = 31
Interventions Experimental group: methylprednisolone
Dose: .......given in a single dose of eight pills (4-mg tablets) each morning for 28 days.
32 mg methylprednisolone (equivalent to 40 mg prednisolone)
In patients unable to take oral medications, intravenous infusions of the study drugs
were administered daily (methylprednisolone sodium succinate (SoluMedrol) or identical
placebo”. After 4 weeks, four tablets were administered daily for 1 week followed by two
tablets daily for an additional week; then therapy was discontinued
Control group: placebo - identical tablets
Additional treatment: “All patients were offered a 3000-caIorie diet. Protein (1 to 1.5 g/
kg body weight) was provided for patients who had no evidence of hepatic encephalopa-
thy. Protein restriction to 20 g/d or less and lactulose therapy were instituted in patients
with signs of hepatic encephalopathy. Ascites was managed with sodium restriction or
by the addition of spironolactone in patients who did not respond with diuresis within
5 days
Fluid intake was restricted in patients with hyponatraemia. B-compIex multivitamins
and folic acid (1 mg) were given each day. In patients who developed tremulousness or
delirium tremens, Valium, or oxazepam was administered.”
Duration of treatment: 5 weeks; 28 days - 32 mg. “After 4 weeks, four tablets were
administered daily for 1 week followed by two tablets daily for an additional week; then
therapy was discontinued”
Duration of follow-up after randomisation: at the moment of discharge
Outcomes The trial outcomes were:
• Mortality
• Liver biochemistry
• Adverse events
Notes Letter sent to authors in March 2000. No answer received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A random code was prepared for each of
the four participating institutions such that
within each group of 10 patients, 5 would
receive methylprednisolone and 5 placebo.
......”
Allocation concealment (selection bias) Low risk “the random code sequence was kept by an
independent source”
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “neither the principal investigators nor
their associates were aware of which regi-
men patients received throughout the trial.
”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Data obtained at initial evaluation and fol-
low-up were recorded on standardized data
collection forms that were submitted to the
statistical coordinating center at the end of
each study.... A study overview committee,
chaired by Dr. Hyman Zimmerman, re-
viewed the ongoing results of the study on
a yearly basis from reports generated by the
statistical coordinating center, which had
access to the randomisation codes”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3%
“One patient who received methylpred-
nisolone was belatedly discovered to have
had neither encephalopathy nor elevation
of discriminant function sufficient to meet
the entry criteria and was excluded from
analysis. Of the remaining 66 patients, 64
remained in the hospital for the duration of
the study. Two methylprednisolone recipi-
ents refused to continue in the study. The
first patient signed out of the hospital after
10 days on the trial and was alive at the end
of the study. The second patient was dis-
charged at his insistence after 15 days on
the trial and was given the study drug to
take at home, but he never returned for fol-
low-up. His status at the end of the study
was unknown. He was the only patient lost
to follow-up.”
2/36 prednisolone group / placebo group
0/31
Selective reporting (reporting bias) Low risk All-cause mortality, serious adverse events,
and liver-related mortality were reported
For-profit bias Unclear risk “random sequences for drug or placebo
were submitted to the Upjohn Company
(Kalamazoo, Michigan), which provided
methylprednisolone (Medrol) in 4-mg
tablets and identical placebo tablets as well
as intravenous preparations of methylpred-
nisolone sodium succinate (Solu-Medrol)
and placebo.”
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Other bias Low risk Not suspected
De 2014
Methods A randomised controlled clinical trial
Country: India (the Medical College and Hospital, Kolkata); January 2010 - August
2012
The study protocol was approved by the institutional ethical committee
Participants Demographic characteristics
Age: mean (year) (PTX +prednisolone)/PTX 42.73 (0.43)/41.33 + 7.81
Sex: male
Inclusion criteria and degree of severity
“Patients who had a history of chronic alcohol intake of more than 50 g/day with clinical
and biochemical features of severe alcoholic hepatitis (MDF score ≥ 32 and aspartate
aminotransferase (AST): alanine aminotransferase (ALT) > 2:1 with absolute value of
AST < 500 IU/L and ALT < 200 IU/L)”
Model for end stage liver disease (MELD) score and Glasgow alcoholic hepatitis score
(GAHS) and Child Pugh score were calculated for all participants who were included
in the study
Exclusion criteria
“..Patientswith any other potential etiology of liver injury (acute or chronic viral hepatitis,
autoimmune liver disease, Wilson’s disease) even in the background of chronic alcohol
intake, positive for HIV antibodies or patients with a history of abstinence from alcohol
in the lastmonth, infection, sepsis or spontaneous bacterial peritonitis, acute pancreatitis,
gastrointestinal bleeding, hepatorenal syndrome or any other severe associated disease
such as uncontrolled diabetes mellitus, systemic hypertension, heart failure, pulmonary
disease or malignancy at the time of inclusion or in the previous 3 months”
Randomisation procedure
“The recruited patients were then divided into 2 groups by a computer generated ran-
domization table”
Number of participants randomised
n = 62
“... who fulfilled the inclusion and exclusion criteria and who gave informed written
consent were randomized and divided into 2 groups:
Group 1 (PTX only) had 31 patients
Group 2 (prednisolone plus PTX) had 31 patients.
One patient inGroup 1 developed severe vertigowithin 7 days after starting PTX and one
patient in Group 2 withdrew voluntarily from the study, and hence they were excluded.
Hence, a total of 60 patients, 30 in each group, were considered for the final analysis.”
Prednisolone group
n = 31 (1 voluntary dropped out)
Control group
n = 31 (1 vertigo and withdrew)
Interventions Experimental group: “received prednisolone tablet (Wysolone,Wreath,Mumbai, India)
at a dose of 40 mg once daily for 4 weeks and PTX tablets at a dose of 400 mg thrice
daily for the duration for the first 4 weeks”
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De 2014 (Continued)
Dose: 40 mg prednisolone
Control group: “received PTX (Trental tablets, Sanofi Aventis, Mumbai, India) at a
dose of 400 mg thrice daily orally and a placebo tablet in the place of prednisolone for
the first 4 weeks.”
Dose: 40 mg placebo
Duration of treatment: 12 weeks
“After the initial 4 weeks, the study was opened and the patients allocated to different
groups were revealed. Patients in Group 1 (PTX) who tolerated the drug well, continued
to receive the medication at the same dose for the next 8 weeks and then stopped
After 4 weeks of initial therapy, the dose of prednisolone in Group 2 was tapered by 5
mg/week over a period of 7 weeks and then stopped and received PTX like Group 1
patients”. (Thus, we can use only 3 months.)
Duration of follow-up: 12 months
Outcomes The trial outcomes were:
• Mortality
• Adverse events
• Morbidity
Notes “One patient in Group 1 developed severe vertigo within 7 days after starting PTX,
and one patient in Group 2 withdrew voluntarily from the study and hence they were
excluded. A total of 60 patients, 30 in each group, were considered for the final analysis.
”
Letter sent to SK Mandal 12.10.2016. No reply received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The recruited patients were then divided
into 2 groups by a computer generated ran-
domization table”
Allocation concealment (selection bias) Unclear risk Unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The investigator, who allocated the pa-
tients to the groups, administered the drugs
and collected the clinical and laboratory
data, as well as statisticians were all blinded
regarding the nature of the pharmacother-
apy.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “as well as statisticians were all blinded re-
garding the nature of the pharmacotherapy.
”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1.6%
“One patient in Group 1 developed severe
vertigo within 7 days after starting PTX,
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and one patient in Group 2 withdrew vol-
untarily from the study andhence theywere
excluded.”
1/31 prednisolone/1/31 placebo group
Selective reporting (reporting bias) Low risk All-cause mortality, serious adverse events,
and liver-related mortality are reported
For-profit bias Unclear risk “Prednisolone tablet (Wysolone, Wreath,
Mumbai, India) and ptx (trental tablets,
Sanofi Aventis, Mumbai, India”
Other bias Low risk Not suspected
Depew 1980
Methods A randomised, double-blind, controlled clinical trial
Country: USA, 1977-1979
The study was approved by the Human Experimentation Committee of the JohnWesley
County Hospital
Analyses were performed according to intention-to-treat method
Sample size calculation was reported.
Participants Demographic characteristics:
Age: (mean) + SD: 49.8 + 2.1 in the treatment group, 48.2 + 2.3 in the placebo group
Sex: (male (%)): 10 (67)/6 (43), hepatic encephalopathy %: 100/100; ascites %: 87/92
Inclusion criteria and degree of severity
“.... all patients were alcohol abusers from the lower socioeconomic strata with a clinical
diagnosis of severe alcoholic hepatitis manifested by hepatomegaly, leukocytosis, and a
serum-bilirubin greater than 5mg/dL, spontaneous hepatic encephalopathy occurring in
the absence of gastrointestinal haemorrhage, sedation, diuretic usage, or major electrolyte
disturbances.”
Exclusion criteria
“Severe diabetes, active tuberculosis, and serious bacterial infection prevented participa-
tion in the trial”
Liver biopsy was not required.
Randomisation procedure
Unclear. It is not described. However, it reads: “All patients fulfilling the criteria who
gave informed consent were randomised into two treatment protocols” and “...to avoid
introducing bias based on the presence of the hepatorenal syndrome, the randomisation
procedure was stratified to distinguish those with a serum creatinine greater than 2.5
mg/dL.”
Number of participants randomised
n = 28
Prednisolone group: n = 15
Control group: n = 13
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Interventions Prednisolone group: prednisolone
Dose: 40 mg daily by mouth
Control group: placebo
Dose: 40 mg daily by mouth
Duration of treatment: “....28 days followed by tapered withdrawal over the ensuing 14
days.”
Additional treatment: “none of the patients received prophylactic isoniazid. Supportive
measures were attention to fluid and electrolyte balance, multiple vitamin supplementa-
tion, and parenteral glucose administration when food intake was poor. Encephalopathy
was treated with catharsis, protein restriction, and oral neomycin.”
Duration of treatment: 6 weeks to 28 days followed by tapered withdrawal over the
ensuing 14 days
Duration of follow-up: 6 weeks
Outcomes The trial outcomes were:
• Mortality
• Liver biochemistry
• Liver histology
• Adverse events
Notes Letter sent to authors in March 2000. No answer received. No further attempts were
made as the trial was conducted between 1977-1979
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described. “All patients fulfilling the
criteria who gave informed consent were
randomised into two treatment protocols”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Neither the principal investigators nor
the physicians attending the patients were
aware of the identity of the coded drugs.
Provision was made for breaking the code
if serious complications developed which
could be related to steroid therapy”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no withdrawals and dropouts
Selective reporting (reporting bias) Low risk All-cause mortality, serious adverse events,
and liver-related mortality were reported
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For-profit bias Unclear risk Not reported
Other bias Low risk None suspected
Helman 1971
Methods Randomised controlled trial
Country: USA
Analyses were performed according to intention-to-treat method
Sample size calculation was not reported.
Participants Demographic characteristics:
Age: (average) 47.8 years, with a range of 30 to 67 years
Sex : male 12, female 25
Inclusion criteria and degree of severity
“. .... the diagnosis of alcoholic hepatitis was confirmed in all patients by percutaneous
needle biopsy....Seventy per cent of patients had anaemia on admission. The anaemia
was attributed to folate deficiency, blood loss, alcoholism, and haemolysis.”
Exclusion criteria
“Patients with clinical evidence of alcoholic hepatitis were excluded from the trial if a
biopsy could not be obtained within the first week of hospitalisation, if gastrointestinal
bleeding requiring transfusion occurred during this period, or if the purified protein
derivative test was positive.”
The authors reported that participants were classified into three groups, according to
clinical severity of their disease. “Group I were severely ill- manifesting precoma or coma,
group 2 -were moderately ill,but no evidence of encephalopathy, group 3 - asymptomatic
ambulatory patients.”
Randomisation procedure
“... patients were selected by a random, double-blind technique....Drug treatment was
randomly determined by the hospital pharmacist, without informing physicians, nurses,
or patients until completion of the study”
Number of participants randomised
n = 37, divided in 3 groups according to the severity of the disease
Prednisolone group: n = 20
Control group: n = 17
Interventions Experimental group: prednisolone daily
Dose: 40 mg
Control group: daily lactose placebo
Dose: 40 mg
Additional intervention: “all patients were treated with bed rest, a high protein (100 g)
and high calorie diet (3 000Kcal) when tolerated and vitamin supplementation including
folic acid. Sodium restriction was instituted and all patients with ascites and oedema
were treated with diuretics.”
Duration of treatment: 6 weeks: 4 weeks and 2-week period tapered
Duration of follow-up after randomisation: 4 months
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Outcomes The trial outcomes were
• Mortality
• Liver biochemistry
• Liver histology
• Adverse events
Notes “prednisolone and lactose placebo provided by Upjohn Co, Kalamazoo, Mich”
Letter sent to authors in March 2000. No answer received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described. It only reads: “patients were
selected by a random, double-blind tech-
nique....”
Allocation concealment (selection bias) Low risk “Drug treatment was randomly deter-
mined by the hospital pharmacist, without
informing physicians, nurses, or patients
until completion of the study ”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “.....The treatment code was broken dur-
ing the study in only one case because of a
medical emergency”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk None of the participants withdrew or
dropped out
Selective reporting (reporting bias) Low risk All-cause mortality was reported
For-profit bias Unclear risk “tablets 40 mg of prednisolone daily or
lactose placebo (provided by Upjohn Co,
Kalamazoo, Mich)”
Other bias Low risk None suspected
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Methods Randomised, double-blind clinical trial with parallel-group design (3 groups)
Country: USA
Analyses were not performed according to the intention-to-treat principle
Sample size calculation was not reported.
Participants Demographic characteristics
Age: (mean + SD): 40 + 8.5 in the treatment group and 42.3 + 11.1 in the control group
Sex: 12 men (50%) in the treatment group and 23 men (74%) in the control group
Inclusion criteria and degree of severity
People with a history of long-standing and recent alcoholism were referred to the Liver
Service (The JohnsHopkinsHospital). A percutaneous liver biopsy was performed unless
precluded by coagulation abnormalities. Alcoholic hepatitis was defined histologically
as an inflammatory hepatic disease with cell swelling and hydropic change, cell necrosis,
and polymorphonuclear leukocytic infiltration
Exclusion criteria
People with active gastro-intestinal haemorrhage, pancreatitis, history of peptic ulcer,
active infection, presence of hepatitis B infection, or history of previous viral hepatitis
were excluded. Maddrey’s discriminant-function. All people had wedged hepatic venous
pressure determination
Randomisation procedure
“Patients were randomized for treatment within three groups based on apparent severity
of disease. Random drug sequences were arranged within each group.”
Number of participants randomised
n = 57
“Patients were randomised for treatment within three groups based on apparent severity
of disease
Group A (moderately ill), serum bilirubin > 3 mg per dL; hepatomegaly; and clotting
factors adequate to allow liver biopsy
Group B (more severely ill), hyperbilirubinaemia and hepatomegaly as in A with addi-
tional presence of ascites and/or hepatic encephalopathy, but coagulation studies ade-
quate for liver biopsy
Group C (severely ill), hyperbilirubinaemia and hepatomegaly as in A and B, with or
without ascites and/or hepatic encephalopathy, but coagulation abnormalities precluded
liver biopsy.”
Prednisolone group: n = 25
Control group: n = 32
Interventions Experimental group:
Dose: 40 mg/d orally (eight tablets 5 mg each every morning)
Control group: identical placebo tablets
Additional interventions to the trial groups: all trial participants were offered a 3000
calorie diet. Protein (1 g to 1.5 g per kg) was provided for people with no evidence of
hepatic encephalopathy. In people with encephalopathy, protein restriction to 20 g/d or
less and lactulose therapy. Ascites was managed with sodium restriction alone or with
the addition of spironolactone in those who did not respond with diuresis in 5 days. All
participants initially received 100 mg
of thiamine intramuscularly. B-complex multivitamins and folic acid U mg) were given
each day
Duration of treatment: from 28 to 32 days
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Follow-up: until discharge
Outcomes The trial outcomeswere“factors important in determining outcome in alcoholic hepatitis
and to evaluate further the effects of corticosteroid therapy on early mortality and on the
progression to cirrhosis, as reflected by histological changes and wedged hepatic venous
pressure.”
Reported outcomes in the trial
• Early mortality
• Complications of therapy
• Liver function and hematological tests
• Wedged hepatic venous pressure
• Factors associated with a fatal outcome
• Discriminant function analysis
Notes This study was supported by Research Grant AA00201 from the National Institute of
Alcohol Abuse and Alcoholism of the National Institutes of Health, and by Grant RR-
35 from the Clinical Research Centers Program, United States Public Health Service.
Prednisolone and placebo tablets were provided by theDivision of Steroid Research, The
Upjohn Company, Kalamazoo, Mich
Letter sent to authors in March 2000. No answer received. No further attempts were
made
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomised for treatment
within three groups based on apparent
severity of disease. Random drug sequences
were arranged within each group”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Prednisolone (5 mg) or identical placebo
tablets were given in a single dose of 8
pills each morning for 28 to 32 days.
(Prednisolone (5mg) and identical placebo
tablets were provided by the Division of
Steroid Research, The Upjohn Company,
Kalamazoo, Mich.). The investigators were
not aware of which regimen the patient was
receiving until the completion of the study.
”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
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Incomplete outcome data (attrition bias)
All outcomes
Low risk 3.5% dropped out or were withdrawn, i.
e. “Two additional patients were removed
from the study after randomisation. One
patient who was randomised to the placebo
group bled from oesophageal varices be-
fore receiving the study drug. He sub-
sequently stopped bleeding and survived.
Another patient had an episode of up-
per gastrointestinal haemorrhage presum-
ably from oesophageal varices after receiv-
ing prednisolone for 9 days and the drug
was stopped.”
1/25 prednisolone group and 1/32 placebo
group
Selective reporting (reporting bias) Low risk All-cause mortality, serious adverse events,
and liver-related mortality were reported
For-profit bias Unclear risk Prednisolone and placebo tablets were pro-
vided by the Division of Steroid Research,
The Upjohn Company, Kalamazoo, Mich.
However, no further details were provided
Other bias Low risk None suspected
Mendenhall 1977
Methods A prospective, randomised clinical trial (three intervention groups)
Country: USA
Intention-to-treat analysis: not mentioned
Sample size calculation was not reported.
Participants Demographic characteristics
Age: not reported
Sex: not reported; most probably men as they came from V.A. (Veteran Affairs) Medical
Centers
Inclusion criteria and degree of severity
• History of daily ethanol ingestion > 100 g/d for ≥ 1 year;
• Hepatomegaly (> 12 cm) and significant jaundice (bilirubin > 5 mg %)
• Liver biopsy was obtained in about 70% of participants to confirm the diagnosis
Exclusion criteria
Not described
Randomisation procedure
Not described, but mentioned that “regimens were chosen randomly and blinded so that
neither physician nor patient was aware of the treatment modality”
Number of participants randomised
n = 46
29 (n = prednisolone and placebo) + 17 (n = oxandrolone)
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Prednisolone group: n = 12 (all severe alcoholic hepatitis)
Control group: n = 17 (all severe alcoholic hepatitis)
Interventions Experimental group: “prednisolone 60 mg/d x 5, then decreased over a 16 day period”
Dose: 60 mg
Placebo group: placebo
Dose: unknown
Additional treatment: supportive care
Duration of treatment: 21 days
Duration of follow-up: at the moment of discharge
Outcomes The trial outcomes were
• Mortality
• Liver biochemistry
Notes Letter sent to study authors in 2006. No answer received.
Only published as an abstract
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “.....regimens were chosen randomly”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “blinded so that neither physician nor pa-
tient was aware of the treatment modality”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk “one additional mortality withdrew from
the study on the 8 day” (not mentioned
from what group out of 50 participants
17 participants were treated with oxan-
drolone
Selective reporting (reporting bias) Low risk All-cause mortality was reported
For-profit bias Unclear risk Not reported
Other bias Low risk None suspected
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Methods A co-operative, multicentre, randomised clinical trial (three intervention groups)
Country: USA, 1980-1983
Intention-to-treat analysis
Sample size calculation was reported.
Participants Demographic characteristics
Age: (mean 90) prednisolone group 51.5 + 8.2; (mean 88) placebo group 50.4 + 9.2
Sex: male
Inclusion criteria and degree of severity
Men hospitalised at 6 Veterans Administration Medical Centers in whom diagnosis of
moderate or severe alcoholic hepatitis was based on conventional clinical and laboratory
changes of this disease
“Histological confirmation was not required, so that severely ill patients were not ex-
cluded.”
Criteria to classify severity: “the degree of jaundice (bilirubin) and coagulopathy (pro-
thrombin time)”
Exclusion criteria
• “..conditions that contradicted corticosteroid therapy: severe infections, active
peptic ulcer disease,or insulin - dependent diabetes mellitus) or if they had taken
corticosteroids within the preceding three months”
• “a positive test for hepatitis B surface antigen; clinical or historical evidence of
recent parenteral drug abuse, intractable congestive heart failure, neoplasms that
commonly metastasize to the liver or nonalcoholic liver diseases”
Randomisation procedure
“...One hundred thirty-two patients with moderate disease and 131 with severe dis-
ease were randomly assigned to one of three treatments: prednisolone, oxandrolone, or
placebo...Treatment assignment were made by the Coordinating Center (Hines, Ill.)The
random assignment of treatments was balanced within each hospital, as well as according
to disease severity.”
Number of participants randomised
178 (n = prednisolone and placebo) + 85 (n = oxandrolone)
Prednisolone group: n = 90 (moderate 46, severe 44)
Control group: n = 88 (moderate 45, severe 43)
Interventions Experimental group: prednisolone
Dose: “60 mg per day for four days; 40 mg per day for four days; 30 mg per day for four
days; 20 mg per day for four days; 10 mg per day for seven days; 5 mg per day for seven
final days”
Control group: corresponding placebos
Duration of treatment: 30 days
When possible, participants were evaluated monthly at outpatient clinics. If alcoholic
hepatitis recurred and required re-hospitalisation, the person was reassigned to the same
therapy for 30 days with his permission
Duration of follow-up after randomisation: 1 year (350 days for prednisolone group
)
Outcomes The trial outcomes were
• Mortality
• Liver complications
• Liver biochemistry
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• Adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Treatment assignment was made by the
CoordinatingCenter (Hines, Ill.). The ran-
dom assignment of treatments was bal-
anced within each hospital, as well as ac-
cording to disease severity”
Allocation concealment (selection bias) Low risk “Treatment assignment were made by the
Coordinating Center (Hines,Ill.)”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Medication was packed into unit dose
kits at the Veterans Administration Center
Pharmacy(Albuquerque, N.M.). The pa-
tient, physician and the local hospital phar-
macy had no knowledge of the specific
medication in use”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4.5%
“Ten patients withdrew from the study
before completing treatment (5 given
placebo, 3 prednisolone). However, these
patients were included in the outcome as-
sessment”
3/ 90 prednisolone group/ 5/88 control
group
“324 days...37 patients were lost to follow-
up: 13 given placebo, 11 prednisolone”
Selective reporting (reporting bias) Low risk All-cause mortality, serious adverse events,
and liver-related mortality are reported
For-profit bias Unclear risk “Matching placebos were prepared for each
of these medications by Upjohn Company
and G.D. Searle and Company.”
Other bias Low risk None suspected
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Porter 1971
Methods A prospective, double-blind, controlled pilot trial
Country: USA
Analyses were not performed according to the intention-to-treat method
Sample size calculation was not reported.
Participants Demographic characteristics steroid/placebo group
Age (years) 44.6 + 4.4/49.5 + 8.9 (age range 27 to 61 years)
Sex: male 13/7 (64%/67%)
Inclusion criteria and degree of severity:
“A history of recent heavy alcohol ingestion
a serum bilirubin concentration of 5 mg per 100 mL or more
clinical and laboratory deterioration over the first five hospital days, a striking lack of
improvement in the patient’s clinical and biochemical status over the same period, or
rapid marked deterioration in less than 24 hours
for admission to the study all three absolute criteria were required
In addition, two or more major criteria or one major and four or more minor criteria
had to be met. The major criteria were liver biopsy showing alcoholic hepatitis; hepatic
encephalopathy (including asterixis); persistent or progressive azotaemia not explained
by another process, and total bilirubin levels > 20 mg/100 mL. The minor criteria
for inclusion were fever that was not obviously secondary to another process; white
blood count > 12,000 not obviously secondary to another process; anorexia or nausea
or vomiting; palpable hepatomegaly; palpable splenomegaly; oesophageal varices; spider
angiomas, edema or ascites; palmar erythema and a prothrombin time prolonged three
or more seconds over control
The Australia antigen was absent from the serum of all 16 patients in whom it was
sought. Before the trial, a percutaneous needle biopsy of the liver was performed if the
prothrombin time was not prolonged more than four seconds over control and there was
no clinical bleeding tendency
Exclusion criteria active gastrointestinal bleeding, pancreatitis, radiological evidence of
peptic-ulcer disease, active or questionably active pulmonary tuberculosis and potentially
life threatening bacterial infection
Randomisation procedure: ”the case was randomised into one of the two treatment
groups. Both the steroid (6- methyl prednisolone, or Medrol) and the placebo (lactose)
were packaged and coded by number in both parenteral and oral forms (prepared and
supplied through the courtesy of the Upjohn Co, Kalamazoo,Mich)and randomisation
was achieved by a number drawn from a pool. Neither patients nor physicians knew
which form of treatment was used until the study had been completed, when the code
was broken.“
Number of participants randomised: n = 23 (20) ”23 accepted to participate, but 3
died within 36 hours of the start of therapy, and were excluded from the analysis before
the code was broken, and did not receive adequate medication. The final series consisted
of 20 patients“
Prednisolone group: n = 11
Placebo group: n = 9
Interventions Prednisolone group: ”6-methyl-prednisolone (or Medrol) 40 mg per day (equivalent to
50 mg prednisolone, or 200 mg hydrocortisone) in three divided doses, parenterally for
the first 10 days. If clinical improvement occurred over this interval and if nausea and
vomiting were absent the drug was administered orally, and the dose gradually tapered
(decreased every second day by 4 mg for the 11th to the 18th days, by 2 mg for the
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19th to 30th days and every third day by 2 mg for the 31st to 45th days). If there was
no clinical improvement within 10 days. The initial parenteral dose of 40 mg daily was
continued until improvement or death occurred.“
Dose: 50 mg prednisolone
Placebo group: placebo(lactose). ”...packaged and coded by number in both parenteral
and oral forms (prepared and supplied through the courtesy of the Upjohn Co, Kalama-
zoo, Mich)“
Additional treatment: ”early in the study only the patients with a positive intermediate
strength PPD test or a suspicious chest film were given isoniazid coverage , however, later
in the study, all patients were so treated“
”general supportive care required in hepatic decompensation. Special attention was given
to fluid and electrolyte balance , prompt treatment of hepatic encephalopathy and re-
peated evaluation for infection... most patients had daily estimation of the caloric and
protein intake by a hospital dietitian... who were unable to take oral nutrition received
parenterally a minimum of 400 calories per day as glucose
Duration of treatment and of follow-up: 45 days after randomisation
Outcomes The trial outcomes were:
• Mortality
• Liver biochemistry
• Liver histology
• Adverse events
Notes Country: USA
Letter sent to study authors in March 2000. No answer received
“Twenty-three patients were accepted for studying. However, three died within 36 hours
of the start of the therapy and were excluded from analysis before the code was broken
because they did not receive adequate medication.”
Supported in part by a gastroenterology-research training grant (AM-05099) from the
National Institute of Artrithis and Metabolic Diseases (a portion of this work was con-
ducted within the Clinical Research Center of the University of Washington, with sup-
port by a grant MO1 FR-37 from the National Institutes of Health
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “... randomisation was achieved by a num-
ber drawn from a pool”
Allocation concealment (selection bias) Low risk “the case was randomised into one of the
two treatment groups. Both the steroid (6-
methyl prednisolone, or Medrol) and the
placebo (lactose) were packaged and coded
by number in both parenteral and oral
forms (prepared and supplied through the
courtesy of the Upjohn Co, Kalamazoo,
Mich)...”
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Neither patients nor physicians knew
which form of treatment was used until the
study had been completed, when the code
was broken”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “At the conclusion of the study, all needle
biopsy and post-mortem liver specimens
were coded and read in blind review by the
same observer”
Incomplete outcome data (attrition bias)
All outcomes
High risk 13%
“Twenty three patients were accepted for
study, three died within 36 hours of the
start of therapy and were excluded from
analysis before the code was broken be-
cause they didn’t receive adequate medica-
tion. The final series thus consisted of 20
patients ”
Selective reporting (reporting bias) Low risk All-cause mortality, serious adverse events,
and liver-related mortality are reported
For-profit bias Low risk “The drugs were provided by Upjohn Co.,
Kalamazoo, Mich.”
Supported in part by a gastroenterology-
research training grant (AM-05099) from
the National Institute of Artrithis and
Metabolic Diseases (a portion of this work
was conductedwithin theClinical Research
Center of the University of Washington,
with support by a grant MO1 FR-37 from
the National Institutes of Health
Other bias Low risk None suspected.
Ramond 1992
Methods A randomised, double-blind trial
Intention to-treat analysis
“The study was approved by the hospital ethics committees”
Participants Demographic characteristics: 124 alcoholic patients were admitted to 2 centres.
Mean age + SD: 48.1 + 1.3; 48.2 + 1.6
Sex: (male): prednisolone group/placebo group 10/9
Randomisation procedure: “... a random code was prepared by computer for each
participating center. There was a different code formen andwomen in each center, so that
within each group of six patients (male or female), three patients received prednisolone
and three patients placebo. Random sequence of drug or placebo were prepared by the
64Glucocorticosteroids for people with alcoholic hepatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ramond 1992 (Continued)
pharmacists at each hospital”
Inclusion criteria and degree of severity: “all the patients had biopsy proven alcoholic
hepatitis (characterised by hyaline necrosis and infiltration of polymorphonuclear leuco-
cytes) and spontaneous hepatic encephalopathy or a discriminant-function value higher
than 32 (or both).”
“Eight patients died before inclusion in the trial.”
Exclusion criteria “gastrointestinal bleeding or bacterial infection were excluded from
the trial unless they could be effectively treated within 48 hours”
Presence of hepatitis B surface antigen, presence ofHIV antibodies, refusal of liver biopsy,
non-alcoholic hepatitis at histology
Number of participants randomised: n = 65 “65 patients were randomly assigned,
but 4 were excluded- one patient assigned to receive prednisolone was found to have
anguilluliasis and her treatment was stopped one day after her inclusion in the study.
Three patients assigned to placebo were found not to have satisfied the inclusion criteria
. These 4 patients were alive at the end of treatment”
Prednisolone group: n = 33 (analysed 32)
Placebo group: n = 32 (analysed 29)
Interventions Prednisolone group:
“prednisolone (Solupred) in 20 mg tablets and identical placebo were provided by the
pharmacists at each hospital”
Dose: “prednisolone 40 mg (40 mg of prednisolone equivalent to 32 mg of methyl-
prednisolone) was given in a single dose of two pills each morning for 28 days”, if the
participant was unable to take oral medication, “received intravenous infusions of pred-
nisolone (Hydrocortancyl) or placebo prepared by the pharmacists and administered by
the pharmacist and administered by the attending physician.”
Placebo group:
“identical placebo was given in a single dose of two pills”
Additional treatment:
“All patients were provided with 3,000 Kcal containing one gram protein/kg. Pa-
tients with hepatic encephalopathy received lactulose therapy. Ascites was managed with
sodium restriction or by the spironolactone to the treatment regimen” “B complex mul-
tivitamins, folic acid, and antiacids were given each day”
Duration of treatment: 28 days
Duration of follow-up: 8 weeks
Outcomes The trial outcomes were:
• Mortality
• Liver biochemistry
• Liver histology
• Adverse events
Notes Country: France. From March 1987-June 1990
Letter sent to study authors in March 2000. No answer received
The trial was stopped at the first interim analysis conducted after inclusion of 61 par-
ticipants out of the planned 130 participants. The authors used an alpha error below 0.
025. This is too high a value to prevent early stopping at a random high
“Drug therapy was interrupted by the attending physician if there was severe bacterial
infection or gastrointestinal bleeding, or if a corticosteroid-related complication was
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suspected... in patients with such complications the remaining tablets of the study drug
were replaced with placebo tablets provided by the pharmacist (the only person who
knew which regimen the patient had received first). The principal investigator and their
associates were not aware of randomisation procedure or of the medication that the
patients were receiving throughout the trial.”
“65 patients were randomly assigned, but 4 were excluded - one patient assigned to
receive prednisolone was found to have anguilluliasis and her treatment was stopped one
day after her inclusion in the study. Three patients assigned to placebo were found not to
have satisfied the inclusion criteria. These 4 patients were alive at the end of treatment.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “a random code was prepared by com-
puter for each participating centre... There
was a different code prepared for men and
women in each center, so that within each
group of six patients (male and female)
, three patients received prednisolone and
three received placebo”
Allocation concealment (selection bias) Low risk “a random code was prepared by computer
for each participating centre. Random se-
quences of drug or placebo were prepared
by the pharmacist at each hospital”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “a random code was prepared by computer
for each participating centre. Random se-
quences of drug or placebo were prepared
by the pharmacist at each hospital”
“prednisolone (Solupred) in 20 mg tablets
and identical placebo were provided by the
pharmacists at each hospital”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information was provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1.5%
1 woman left the hospital and then “she
was re hospitalised 56 days after enrolment
and left again the following day. She was
the only patient lost to follow up”
1/33 prednisolone group 0/32 placebo
group
Selective reporting (reporting bias) Low risk All-cause mortality, serious adverse events,
and liver-related mortality were reported
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For-profit bias Unclear risk Prednisolone tablets and placebo were pro-
vided by Laboratoire Houdé (Paris)
Other bias Low risk Not suspected
Richardet 1993
Methods A randomised clinical trial with a cross-over design
Intention to-treat analysis: not mentioned
Sample size calculation was not reported
Participants Demographic characteristics: no information.
Inclusion criteria and degree of severity: non-infected patients with histologically
proven alcoholic hepatitis. All patients had severe hepatic failure (prothrombin time <
50%, or bilirubin > 5.6 mg/dL, or encephalopathy)
Number of participants randomised: 23
Glucocorticosteroid group: 12 participants
Placebo group: 11 participants
Interventions Prednisolone group: prednisolone 40 mg daily
Control group: placebo 40 mg daily
Duration of treatment:
Prednisolone group: 1 week of treatment followed by one week of no treatment
Control group: 1 week of no treatment followed by one week of treatment
After that, both groups received glucocorticosteroids for three weeks
Duration of follow-up: at discharge from hospital (three months)
Outcomes The trial outcomes were:
• Mortality
• Liver biochemistry
Notes Country: France.
Letter sent to study authors in 2006. No answer received.
Only published as abstract
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information
Selective reporting (reporting bias) Unclear risk No information
For-profit bias Unclear risk Not reported
Other bias Unclear risk No information
Shumaker 1978
Methods A prospective, double-blind, randomised clinical trial
Sample size calculation was not reported.
Intention-to-treat analysis: not mentioned, but presumably used
Participants Demographic characteristics:
mean age + SD: 47/43
Sex: male were 25% in the glucocorticosteroid group and 44% in the placebo group
Inclusion criteria and degree of severity:
”history of recent heavy alcoholic ingestion, serum bilirubin greater than 5 mg %, hos-
pitalisation for at least 5 days without improvement in liver tests; or rapid deterioration
of the clinical condition during a 24-hour period while under observation. In addition,
a patient had to have a minimum of two “major criteria” or one “major” and two “mi-
nor” criteria to be placed in the study. The major criteria were a liver biopsy showing
alcoholic hepatitis (with or without Mallory bodies), hepatic encephalopathy, azotaemia
unexplained by another process (BUN [blood urea nitrogen] > 20 mg % or creatinine >
1.5 mg % ), hyperbilirubinaemia (> 20 mg%) and prothrombin time prolonged more
than four seconds over control; and unresponsive to parenteral administration of vitamin
K. The minor criteria included fever not obviously secondary to another process, WBC
(white blood count) > 12,000, hepatomegaly (span greater than 14 cm), splenomegaly,
or liver stigmas (spider telangiectasias, palmar erythema, ascites, edema, etc)“
....”a positive HBAg did not exclude them from the study if a percutaneous liver biopsy
confirmed alcoholic hepatitis“
Exclusion criteria:
”Patients were not considered for the trial if their SGOT [serum glutamic oxaloacetic
transaminase] was greater than 500....Patients were rejected from the study if they mani-
fested active gastrointestinal bleeding, pancreatitis, X-ray evidence of peptic ulcer disease,
active or questionably active tuberculosis, active infection, or severe psychiatric disorder“
Randomisation procedure:
”The patient was then randomised into a predetermined code provided by the drug
manufacturer. Immediately prior to randomisation, patients were stratified into two
categories based on the presence or abstinence of criteria permitting liver biopsy“ the
purpose of this procedure was to provide comparable case material for both steroid and
placebo control groups.in the absence of other contradictions, patients with prothrombin
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times less than four seconds prolonged were placed in the ”Biopsy feasible“ group (n =
10) whether or not they agreed to a biopsy. All other patients constituted the ”Biopsy-
Disallowed“ group (n = 17)”
Number of participants randomised: 27
Prednisolone group: n = 12
Control group: n = 15
Interventions Prednisolone group: “80 mg of 6-methylprednisolone or equivalent number of placebo
tablets (or parenteral therapy of the same dosage intravenously if gastrointestinal function
precluded oral intake) for four to seven days; themedicationwas then tapered on a flexible
schedule with cessation of therapy planned for four weeks unless death or complications”
Dose: 100 mg prednisolone
Control group: placebo
Additional interventions to the trial groups: “Both groups received comparable sup-
portive care required in hepatic decompensation”
All participants with positive tuberculin tests were treated with INH 300 mg daily, and
50 mg of pyridoxine daily
Duration of treatment: 5 weeks; participants were placed on treatment for 4-7 days.
Then the medication was tapered on flexible schedule with cessation of therapy planned
for 4 weeks unless death or complication intervened.
Duration of follow-up: until the moment of discharge
Outcomes The trial outcomes were:
• Mortality
• Liver histology
• Adverse events
Notes Country: USA
Letter sent to study authors in March 2000. No answer received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk “The patient was then randomised into a
predetermined code provided by the drug
manufacturer”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind: “80 mg of 6-methylpred-
nisolone or equivalent number of placebo
tablets (or parenteral therapy of the same
dosage intravenously if gastrointestinal
function precluded oral intake”
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Clinical evaluation was carried out by ju-
nior staff physicians blinded to treatment
status of the patients.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3.7 % “a steroid treated patient voluntarily
withdrew from the study after eight days
but was retained for statistical purposes”
1/12 prednisolone group; 0/15 control
group
Selective reporting (reporting bias) Low risk All-cause mortality, serious adverse events,
and liver-related mortality were reported
For-profit bias Unclear risk “The patient was then randomised into a
predetermined code provided by the drug
manufacturer. (Upjohn Co., Kalamazoo,
MI, prepared and supplied the medication
and placebo.”
Other bias Low risk None suspected
Theodossi 1982
Methods A randomised controlled trial
Analyses were not by intention-to-treat method.
Sample size calculation was not reported.
Participants Demographic characteristics:
Sex: men/women prednisolone group: 19/8, control group 12/16
Age: not mentioned
Inclusion criteria and degree of severity: “patients had to satisfy the following criteria:
- a history of alcohol intake of about 80 g or more daily for at least five years,
- a serum bilirubin concentration greater than 80 pmol/l (normal up to 20 timol/L),
- a serum aspartate transaminase level at least twice the upper limit of normal (normal
up to 40 IU/1),
- a prothrombin time prolonged by at least nine seconds.”
“Gastrointestinal bleeding, renal failure, and sepsis did not invalidate entry.”
Exclusion criteria:
“Patients with hepatoma and those with other diseases such as recent myocardial in-
farction, an accompanying cerebrovascular accident including evidence of subdural
hematoma, and active tuberculosis”
Randomisation procedure
“Patients .... referred from other hospitals because of the severity of their illness. Patients
were allocated by random sealed envelope technique to a control or treatment group...”
Number of patients: 60 (55). They were referred from other hospitals because of the
severity of their illness (after excluded patients from the analyses because of doubts in
initial diagnosis)
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Prednisolone group: n = 28 (27)
Control group: n = 32 (28)
Interventions Prednisolone group: intravenous methylprednisolone 1 g daily for three days
Dose: 1.25 g prednisolone
Control group: no intervention
Additional treatment: “Patients who were too ill to take the standard hospital diet
received a minimum of 2000 calories as intravenous 20% glucose. Encephalopathy was
treated with protein restriction (maximum of 20 g/day), lactulose (15 to 30 mL twice
daily), and daily magnesium sulphate enemas”
Duration of treatment: 3 days
Duration of follow-up: “there was a little difference between the groups in the mean
length of stay in hospital (treatment group 24.2 days and control group 28.1 days)”
Outcomes The trial outcomes were:
• Mortality
• Liver biochemistry
• Adverse events
Notes Country: UK
Letter sent to study authors in March 2000. No answer received
“Of the 60 patients who satisfied the entry criteria, one in the treatment group and four
in the control group were excluded from the final analysis because subsequent findings
in four cases cast doubt on the initial diagnosis, and one patient was later found to have
been given corticosteroids at the referring hospital. Thus there were 27 patients in the
treatment and 28 in the control group.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk “Patients were allocated by random sealed
envelope technique to a control or treat-
ment group,...”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
“Patients were allocated by random sealed
envelope technique to a control or treat-
ment group, the latter receiving intra-
venous methylprednisolone 1 g daily for
three days.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
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Incomplete outcome data (attrition bias)
All outcomes
High risk 8%
“Of the 60 patients who satisfied the en-
try criteria, one in the treatment group and
four in the control group were excluded
from the final analysis because subsequent
findings in four cases cast doubt on the
initial diagnosis, and one patient was later
found to have been given corticosteroids at
the referring hospital. Thus there were 27
patients in the treatment and 28 in the con-
trol group.”
1/28 prednisolone and 4/32 control group
Selective reporting (reporting bias) Low risk All-cause mortality, serious adverse events,
and liver-related mortality were reported
For-profit bias Unclear risk Not reported
Other bias Low risk None suspected
Thursz 2015
Methods Multicentre, randomised trial with a 2-by-2 factorial design (09/MRE09/59)
Country: UK (65 hospitals). January 2011-February 2014
Analyses were performed according to intention-to-treat basis
Sample size calculation was reported.
Participants Demographic characteristics
Age: (mean) + SD: glucocorticosteroids group/control group 49.3 ± 10.6; 48.6 ± 9.8/
47.9 ± 10.2; 48.8 ± 10.3
Sex (male (%)): glucocorticosteroids group/control group 359 (65,6%)/326 (59,8%)
Hepatic encephalopathy (%): 152/143 (28%/26%)
Inclusion criteria and degree of severity
”all patients were alcohol abusers with a clinical diagnosis of severe alcoholic hepatitis
manifested by hepatomegaly, leukocytosis, and a serum-bilirubin greater than 5 mg/dL,
spontaneous hepatic encephalopathy“
• Age of ≥ 18 years
• Clinical diagnosis of alcoholic hepatitis
• Average alcohol consumption of > 80 g/d for men and > 60 g/d for women,
• Serum bilirubin level > 80 µmol/L (4.7 mg/dL)
• Discriminant function of ≥ 32
Exclusion criteria
• Jaundice for > 3 months
• Cessation of alcohol consumption for > 2 months before randomisation
• Presence of other causes of liver disease
• Serum aspartate aminotransferase level > 500 IU/L or serum alanine transaminase
level > 300 IU/L
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• Previous entry into the study within the preceding 6 months
Randomisation procedure
”...A web-based computer system (Tenalea, Forms-Vision) was used to enrol eligible
patients and randomly assign them to study groups. The randomization schedule was
created with the use of Stata software, version 11 (StataCorp). Randomization was per-
formed with a block size of four, with stratification according to geographic area and
risk category. The high-risk category consisted of patients who had an occurrence of
gastrointestinal bleeding, renal impairment, or sepsis before randomisation. All other
patients were assigned to the intermediate-risk category.“
Number of participants randomised
n = 1103 (”...1103 patients underwent randomisation (data from 1053 were available
for the primary end-point analysis..“)
Prednisolone group: 274 + 277
Control group: 276 + 276
Interventions Experimental groups: ”the second group receiving 40 mg of prednisolone daily and a
pentoxifylline-matched placebo (n = 277), the fourth group receiving 40 mg of pred-
nisolone daily, and 400 mg of pentoxifylline three times daily (n = 274)
Dose: 40 mg
Control groups: “one group receiving a pentoxifylline matched placebo and a pred-
nisolone matched placebo, placebo (n = 276). The third group receiving 400 mg of
pentoxifylline three times daily and prednisolone matched placebo (n = 274)”
Additional treatment: “Standard supportive care and nutritional support were given to
each patient. The clinician responsible for each patient made the decision regarding other
treatments, such as terlipressin for patients in whom hepatorenal failure was developing,
acid suppression for prophylaxis against gastrointestinal haemorrhage, antibiotics, and
vitamin supplementation. Patients with renal failure (defined as a creatinine level > 500
µmol per liter [> 5.7 mg per decilitre] or the requirement for renal-replacement therapy)
, active gastrointestinal bleeding, or untreated sepsis, and patients requiring inotropic
support with epinephrine or norepinephrine, were excluded unless the condition stabi-
lized within the first 7 days after admission to the hospital.”
Duration of treatment: 28 days
Duration of follow-up: 1 year
Outcomes The trial outcomes were
• Mortality
• Adverse events
• Quality of life (using the European quality of life -5 dimensions (EQ -5D) score
registered to Eudra CT 2009- 013897-42 and ISRCTN 88782125)
Notes The “European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L): The EQ-
5D-5L is a self-report, multiple choice questionnaire that provides a simple descriptive
profile and a single index value for health status. The EQ-5D-5L essentially consists of
2 pages - the EQ-5D descriptive system (page 2) and the EQ visual analogue scale (EQ
VAS) (page 3). The descriptive system comprises the following 5 dimensions: mobility,
self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has
5 levels: no problems, slight problems, moderate problems, severe problems, and extreme
problems. The EQ VAS records the respondent’s self-rated health on a vertical, visual
analogue scale. The EQ-5D-5L takes only a few minutes to complete
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A summary index with a maximum score of 1 can be derived from these five dimensions
by conversion with a table of scores. The maximum score of 1 indicates the best health
state, by contrast with the scores of individual questions, where higher scores indicate
more severe or frequent problems. In addition, there is a visual analogue scale (VAS) to
indicate the general health status with 100 indicating the best health status.”
“The study was approved by the Multicenter Research Ethics Committee (reference
number 09/MRE09/59), and clinical trial authorizationwas received from theMedicines
andHealthcare ProductsRegulatoryAgency (Fundedby theNational Institute forHealth
Research Health Technology Assessment program; STOPAH EudraCT number, 2009-
013897-42, and Current Controlled Trials number, ISRCTN88782125.)”
“The trial was conducted and reported with fidelity to the protocol, the Medicines for
Human Use (Clinical Trials) Regulations 2004, as amended in 2006, the European
Union Clinical Trials Directive (Directive 2001/20/EC) guidelines, the principles of the
International Conference on Harmonisation Good Clinical Practice under the oversight
of University Hospital Southampton NHS Foundation Trust, and the provisions of the
Declaration of Helsinki
Letter sent to M. Thursz 12 October 2016. No reply received yet
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”A web-based computer system (Tenalea,
Forms-Vision) was used to enrol eligible
patients and randomly assign them to study
groups.“
Allocation concealment (selection bias) Low risk ”The randomization schedule was created
with the use of Stata software, version
11 (StataCorp). Randomization was per-
formed with a block size of four, with strat-
ification according to geographic area and
risk category. “Treatment allocation was
blinded to site staff and the patient by pro-
viding each patientwith a unique four-digit
patient pack number.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded
“The treatment arm was also concealed
to investigators and researchers. Only the
study statisticians were unblinded and this
was for analysis purposes only.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “An independent data monitoring and
ethics committee, whose members were
aware of the group assignments, was con-
vened to review the conduct of the trial
and to analyze primary end-point data, us-
ing prespecified stopping guidelines, after
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the recruitment of 200, 400, and 800 pa-
tients, to avoid continued recruitment in
the event that a definitive result had been
achieved. Data collected by site investiga-
tive teamswere submitted to the clinical tri-
als unit and analysed by study statisticians.
The first author wrote the first draft of the
manuscript, with substantial contributions
from the coauthors. All the authors vouch
for the accuracy and completeness of the
data and analyses.”
Incomplete outcome data (attrition bias)
All outcomes
High risk “At the time the trial was stopped, 33 pa-
tients who underwent randomization dur-
ing the last 90 days of the trial could
not be included in the 90-day or 12-
month analyses. In addition, there were
159 patients who underwent randomiza-
tionwithin 90days to 12months before the
end of trial who could not be included in
12-month analyses. The four groups were
well matched with regard to their baseline
characteristics, including laboratory values
(See Table 1 in the published article). At
28 days, 16% of the patients had died, 1%
had been lost to follow-up, and 2% had
withdrawn from the study. At 90 days, 29%
of the patients (285 of 968 patients) had
died, 5% had been lost to follow-up, 3%
hadwithdrawn, and4%hadnot completed
follow-up owing to cessation of the study.
At 1 year, 56% of the patients (421 of 747
patients) had died or undergone liver trans-
plantation (the latter were 3 patients), 8%
had been lost to follow-up, 4% had with-
drawn, and 20% had not completed fol-
low-up owing to cessation of the study due
to limitations on funding.”
Selective reporting (reporting bias) Low risk All-cause mortality, serious adverse events,
liver-related mortality, and quality of life
were reported
For-profit bias Low risk “Owing to limitations on funding, the trial
was stopped after all enrolled patients had
completed at least 28 days of follow-up.”
“This project was funded by the Na-
tional Institute for Health Research
(NIHR) Health Technology Assessment
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programme. The NIHR Clinical Research
Network provided research nurse support
and the Imperial College Biomedical Re-
search Centre also provided funding.”
Other bias Low risk None suspected
INH = isoniazid; PAS = para-aminosalicylic acid; PPD = purified protein derivative; PTX = pentoxifylline
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alvarez 2004 An observational study (patient series). Thirteen participants with severe alcoholic hepatitis were treated with
systemic glucocorticosteroids and total enteral nutrition
Cabré 2000 A randomised trial of glucocorticosteroids versus nutrition in people with alcoholic hepatitis. Participants
received oral or intravenous prednisolone or enteral nutrition (2000 kcal/d of a chemically defined polymeric
enteral diet enriched in branched-chain amino acids)
Christensen 1981 A quasi-randomised clinical study
Copenhagen 1969 A meta-analysis
Daures 1991 A meta-analysis
Dhanda 2016 A prospective single- centre cohort of patients with severe alcoholic hepatitis treated with steroids - the incidence
and significance of infection
Galambos 1984 Reported in article through private contacts as part of Shumaker 1978
Gill 1984 The trial randomised 10 patients with severe alcoholic hepatitis to prednisolone, testosterone, and amino acid
supplement versus no intervention
Goldis 2000 An observational study (patient series); the authors used a control group from the same centre
Hozo 1996 The trial randomised patients with alcoholic liver cirrhosis to glucocorticosteroids versus placebo
Imperiale 1990 A meta-analysis
Lesesne 1978 A randomised trial of glucocorticosteroids versus nutrition in patients with alcoholic hepatitis. Participants
received glucocorticosteroids plus permission to eat as they wanted or a maximum of 600 kcal/d as intravenous
glucose, while the control group received caloric supplements of at least 1600 kcal/d
76Glucocorticosteroids for people with alcoholic hepatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Mal 1991 Abstract about influence of corticosteroids on the level of serum TNF concentrations
Mendenhall 1993 A chapter on alcoholic hepatitis in a book
Moreno 2014 A multi central study with two groups of comparison of intensive enteral nutrition with complete nutrition, in
both groups receiving prednisolone
Morris 2005 An observational study (patient series)
Naganuma 2014 The trial of granulocytapheresis and leukocytapheresis for the treatment of severe alcoholic hepatitis
Naveau 2004 The trial randomised patients with alcoholic hepatitis to receive infliximab versus placebo. All participants
received prednisone too
Phillips 2001 The trial randomised participants to antioxidants versus glucocorticosteroids
Poynard 1991 A meta-analysis on alcoholic hepatitis
Reynolds 1989 A narrative review on alcoholic hepatitis
Schlichting 1976 A quasi-randomised clinical study
Spahr 2002 The trial randomised patients with alcoholic hepatitis to receive infliximab versus placebo. All participants
received prednisone too
Stewart 2002 The trial stratified participants by gender and glucocorticosteroid use, and then randomised participants to
receive antioxidants versus placebo
Tygstrup 1979 A meta-analysis
Young-Sun Lee A review
TNF: tumour necrosis factor
77Glucocorticosteroids for people with alcoholic hepatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Glucocorticosteroids versus no intervention/placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 15 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Up to 3 months after
randomisation
15 1861 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.70, 1.15]
1.2 At the end of treatment 14 1824 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.66, 1.15]
1.3 At 1 year after
randomisation
3 1343 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.91, 1.17]
2 Health-related quality of life 1 Mean Difference (IV, Random, 95% CI) Totals not selected
2.1 Up to three months 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Up to one year 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Number of participants with
serious adverse events during
treatment
15 1861 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.85, 1.29]
4 Liver-related mortality 15 1861 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.69, 1.14]
4.1 Up to 3 months’ follow-
up after randomisation
15 1861 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.69, 1.14]
5 Any complication 15 1861 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.86, 1.27]
5.1 Number of participants
with complications up to
3 months’ follow-up after
randomisation
15 1861 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.86, 1.27]
6 Number of participants with
non-serious adverse events up
to 3 months’ follow-up after
randomisation
4 160 Risk Ratio (M-H, Fixed, 95% CI) 1.99 [0.72, 5.48]
Comparison 2. Subgroup analysis: all-cause mortality up to 3 months after randomisation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Severity of alcoholic hepatitis 15 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Mild alcoholic hepatitis 4 182 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.58, 1.80]
1.2 Severe alcoholic hepatitis 14 1679 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.73, 1.16]
2 Glucocorticosteroid
(prednisolone) dose
15 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Less than or equal to 40
mg
10 1547 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.50, 1.14]
2.2 More than 40 mg 5 314 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.79, 1.30]
3 Alcoholic hepatitis without
cirrhosis and with cirrhosis
15 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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